

# Stephan Stilgenbauer

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5664937/publications.pdf>

Version: 2024-02-01

616  
papers

39,417  
citations

3334

91  
h-index

3323

184  
g-index

639  
all docs

639  
docs citations

639  
times ranked

22992  
citing authors

#	ARTICLE	IF	CITATIONS
1	Clonal evolution in chronic lymphocytic leukemia is scant in relapsed but accelerated in refractory cases after chemo(immune) therapy. <i>Haematologica</i> , 2022, 107, 604-614.	3.5	11
2	Significant reduced loss of bone mineral density after four vs. six cycles of R-CHOP: an analysis of the FLYER-trial. <i>Leukemia and Lymphoma</i> , 2022, 63, 326-334.	1.3	3
3	The CLL12 trial: ibrutinib vs placebo in treatment-naïve, early-stage chronic lymphocytic leukemia. <i>Blood</i> , 2022, 139, 177-187.	1.4	40
4	Identification of recurrent genomic alterations in the apoptotic machinery in chronic lymphocytic leukemia patients treated with venetoclax monotherapy. <i>American Journal of Hematology</i> , 2022, 97, .	4.1	8
5	KIR2DS1+HLA-C status as a predictive marker for benefit from rituximab: a post-hoc analysis of the RICOVER-60 and CLL8 trials. <i>Lancet Haematology</i> , 2022, 9, e133-e142.	4.6	5
6	Efficacy and Safety of the Combination of Tirabrutinib and Entospletinib With or Without Obinutuzumab in Relapsed Chronic Lymphocytic Leukemia. <i>HemaSphere</i> , 2022, 6, e692.	2.7	6
7	Obinutuzumab (GA-101), ibrutinib, and venetoclax (G1V) frontline treatment for high-risk chronic lymphocytic leukemia. <i>Blood</i> , 2022, 139, 1318-1329.	1.4	30
8	T-cell prolymphocytic leukemia is associated with deregulation of oncogenic microRNAs on transcriptional and epigenetic level. <i>Genes Chromosomes and Cancer</i> , 2022, 61, 432-436.	2.8	1
9	Secondary resistance to idelalisib is characterized by upregulation of IGF1R rather than by MAPK/ERK pathway mutations. <i>Blood</i> , 2022, 139, 3340-3344.	1.4	9
10	Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trial. <i>Leukemia</i> , 2022, 36, 1870-1878.	7.2	47
11	The scaffold protein NEDD9 is necessary for leukemia-cell migration and disease progression in a mouse model of chronic lymphocytic leukemia. <i>Leukemia</i> , 2022, 36, 1794-1805.	7.2	1
12	Efficacy and Safety of Tirabrutinib and Idelalisib With or Without Obinutuzumab in Relapsed Chronic Lymphocytic Leukemia. <i>HemaSphere</i> , 2022, 6, e729.	2.7	3
13	Identification of the atypically modified autoantigen Ars2 as the target of B-cell receptors from activated B-cell-type diffuse large B-cell lymphoma. <i>Haematologica</i> , 2021, 106, 2224-2232.	3.5	11
14	Comparative analysis of targeted next-generation sequencing panels for the detection of gene mutations in chronic lymphocytic leukemia: an ERIC multi-center study. <i>Haematologica</i> , 2021, 106, 682-691.	3.5	10
15	Combining ibrutinib and checkpoint blockade improves CD8+ T-cell function and control of chronic lymphocytic leukemia in Em-TCL1 mice. <i>Haematologica</i> , 2021, 106, 968-977.	3.5	26
16	Clinical activity of abemaciclib in patients with relapsed or refractory mantle cell lymphoma - a phase II study. <i>Haematologica</i> , 2021, 106, 859-862.	3.5	12
17	Bendamustine, followed by ofatumumab and ibrutinib in chronic lymphocytic leukemia (CLL2-BIO): primary endpoint analysis of a multicentre, open-label phase-II trial. <i>Haematologica</i> , 2021, 106, 543-554.	3.5	12
18	Insertion site of central venous catheter correlates with catheter-related infectious events in patients undergoing intensive chemotherapy. <i>Bone Marrow Transplantation</i> , 2021, 56, 195-201.	2.4	4

#	ARTICLE	IF	CITATIONS
19	Higher-order connections between stereotyped subsets: implications for improved patient classification in CLL. <i>Blood</i> , 2021, 137, 1365-1376.	1.4	72
20	Four-Factor Score for Outcome of Ibrutinib Treatment in Chronic Lymphocytic Leukemia: Prognostic Model for Risk Group Definition. <i>Journal of Clinical Oncology</i> , 2021, 39, 551-553.	1.6	4
21	U-RT1 "A new model for Richter transformation. <i>Neoplasia</i> , 2021, 23, 140-148.	5.3	5
22	No increased bleeding events in patients with relapsed chronic lymphocytic leukemia and indolent non-Hodgkin lymphoma treated with idelalisib. <i>Leukemia and Lymphoma</i> , 2021, 62, 837-845.	1.3	1
23	Allogeneic hematopoietic cell transplantation for patients with TP53 mutant or deleted chronic lymphocytic leukemia: Results of a prospective observational study. <i>Bone Marrow Transplantation</i> , 2021, 56, 692-695.	2.4	3
24	LRPAP1 autoantibodies in mantle cell lymphoma are associated with superior outcome. <i>Blood</i> , 2021, 137, 3251-3258.	1.4	9
25	EOMES and IL-10 regulate antitumor activity of T regulatory type 1 CD4+ T cells in chronic lymphocytic leukemia. <i>Leukemia</i> , 2021, 35, 2311-2324.	7.2	27
26	Safety and efficacy of obinutuzumab alone or with chemotherapy in previously untreated or relapsed/refractory chronic lymphocytic leukaemia patients: Final analysis of the Phase IIIb GREEN study. <i>British Journal of Haematology</i> , 2021, 193, 325-338.	2.5	6
27	Integrative prognostic models predict long-term survival after immunochemotherapy in chronic lymphocytic leukemia patients. <i>Haematologica</i> , 2021, , .	3.5	2
28	EOMES is essential for antitumor activity of CD8+ T cells in chronic lymphocytic leukemia. <i>Leukemia</i> , 2021, 35, 3152-3162.	7.2	26
29	MARCKS affects cell motility and response to BTK inhibitors in CLL. <i>Blood</i> , 2021, 138, 544-556.	1.4	14
30	Increased B-cell activity with consumption of activated monocytes in severe COVID-19 patients. <i>European Journal of Immunology</i> , 2021, 51, 1449-1460.	2.9	10
31	B-cell acute lymphoblastic leukemia in patients with chronic lymphocytic leukemia treated with lenalidomide. <i>Blood</i> , 2021, 137, 2267-2271.	1.4	10
32	FDG PET/CT to detect bone marrow involvement in the initial staging of patients with aggressive non-Hodgkin lymphoma: results from the prospective, multicenter PETAL and OPTIMAL>60 trials. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 3550-3559.	6.4	21
33	Discovery of Candidate DNA Methylation Cancer Driver Genes. <i>Cancer Discovery</i> , 2021, 11, 2266-2281.	9.4	42
34	Current Treatment Options in CLL. <i>Cancers</i> , 2021, 13, 2468.	3.7	20
35	Mutational mechanisms shaping the coding and noncoding genome of germinal center derived B-cell lymphomas. <i>Leukemia</i> , 2021, 35, 2002-2016.	7.2	34
36	Clinical, biological, and molecular genetic features of Richter syndrome and prognostic significance: A study of the French Innovative Leukemia Organization. <i>American Journal of Hematology</i> , 2021, 96, E311-E314.	4.1	7

#	ARTICLE	IF	CITATIONS
37	Durable remissions following combined targeted therapy in patients with CLL harboring <i>TP53</i> deletions and/or mutations. <i>Blood</i> , 2021, 138, 1805-1816.	1.4	7
38	Measurable residual disease in chronic lymphocytic leukemia: expert review and consensus recommendations. <i>Leukemia</i> , 2021, 35, 3059-3072.	7.2	40
39	Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial. <i>Journal of Clinical Oncology</i> , 2021, 39, 3441-3452.	1.6	266
40	Longitudinal analyses of CLL in mice identify leukemia-related clonal changes including a <i>Myc</i> gain predicting poor outcome in patients. <i>Leukemia</i> , 2021, , .	7.2	3
41	Tafasitamab combined with idelalisib or venetoclax in patients with CLL previously treated with a BTK inhibitor. <i>Leukemia and Lymphoma</i> , 2021, 62, 3440-3451.	1.3	6
42	Poster: CLL-115: First Results of a Head-to-Head Trial of Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, S220.	0.4	0
43	Killer immunoglobulin-like receptor 2DS5 is associated with recovery from coronavirus disease 2019. <i>Intensive Care Medicine Experimental</i> , 2021, 9, 45.	1.9	5
44	Long-term survival of patients with mantle cell lymphoma after autologous haematopoietic stem-cell transplantation in first remission: a post-hoc analysis of an open-label, multicentre, randomised, phase 3 trial. <i>Lancet Haematology</i> , 2021, 8, e648-e657.	4.6	27
45	Multi-platform profiling characterizes molecular subgroups and resistance networks in chronic lymphocytic leukemia. <i>Nature Communications</i> , 2021, 12, 5395.	12.8	15
46	Minimal Residual Disease Dynamics after Venetoclax-Obinutuzumab Treatment: Extended Off-Treatment Follow-up From the Randomized CLL14 Study. <i>Journal of Clinical Oncology</i> , 2021, 39, 4049-4060.	1.6	74
47	Activation of <i>Notch</i> and <i>Myc</i> Signaling via B-cell "Restricted Depletion of <i>Dnmt3a</i> Generates a Consistent Murine Model of Chronic Lymphocytic Leukemia. <i>Cancer Research</i> , 2021, 81, 6117-6130.	0.9	10
48	IgG seroprevalence of COVID-19 among people living with HIV or at high risk of HIV in southwest Germany: A seroprevalence study. <i>HIV Medicine</i> , 2021, , .	2.2	3
49	Pooled Analysis of First-Line Treatment with Targeted Agents in Patients with Chronic Lymphocytic Leukemia (CLL) Aged 80 Years and Older. <i>Blood</i> , 2021, 138, 1552-1552.	1.4	1
50	Comparison of Tumor Lysis Syndrome (TLS) Risk Reduction and Incidence in Different Venetoclax-Based Combinations within the Randomized Phase 3 GAIA (CLL13) Trial. <i>Blood</i> , 2021, 138, 2639-2639.	1.4	1
51	Characterization of Bruton Tyrosine Kinase Inhibitor (BTKi)-Related Adverse Events in a Head-to-Head Trial of Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2021, 138, 3721-3721.	1.4	0
52	High Resolution Assessment of Minimal Residual Disease (MRD) By Next-Generation Sequencing (NGS) and High-Sensitivity Flow Cytometry (hsFCM) in the Phase 3 GAIA (CLL13) Trial. <i>Blood</i> , 2021, 138, 72-72.	1.4	3
53	A Randomized Phase III Study of Venetoclax-Based Time-Limited Combination Treatments (R <sub>Ve</sub> , G <sub>Ve</sub> , G <sub>IVe</sub> ) Vs Standard Chemoimmunotherapy (CIT: FCR/BR) in Frontline Chronic Lymphocytic Leukemia (CLL) of Fit Patients: First Co-Primary Endpoint Analysis of the International Intergroup GAIA (CLL13) Trial. <i>Blood</i> , 2021, 138, 71-71.	1.4	36
54	Venetoclax plus bendamustine-rituximab or bendamustine-obinutuzumab in chronic lymphocytic leukemia: final results of a phase Ib study (GO28440). <i>Haematologica</i> , 2021, 106, 2834-2844.	3.5	3

#	ARTICLE	IF	CITATIONS
55	Interleukin-10 receptor signaling promotes the maintenance of a PD-1 <sup>int</sup> TCF-1 <sup>+</sup> CD8 <sup>+</sup> T <sub>H</sub> cell population that sustains anti-tumor immunity. <i>Immunity</i> , 2021, 54, 2825-2841.e10.	14.3	57
56	Therapeutic targeting of mutant p53 in pediatric acute lymphoblastic leukemia. <i>Haematologica</i> , 2020, 105, 170-181.	3.5	37
57	Cryptic insertion of <i>MYC</i> exons 2 and 3 into the immunoglobulin heavy chain locus detected by whole genome sequencing in a case of <i>MYC</i> -negative Burkitt lymphoma. <i>Haematologica</i> , 2020, 105, e202-e205.	3.5	24
58	The impact of complex karyotype on the overall survival of patients with relapsed chronic lymphocytic leukemia treated with idelalisib plus rituximab. <i>Leukemia</i> , 2020, 34, 296-300.	7.2	23
59	Oxidative stress as candidate therapeutic target to overcome microenvironmental protection of CLL. <i>Leukemia</i> , 2020, 34, 115-127.	7.2	23
60	Obinutuzumab plus fludarabine and cyclophosphamide in previously untreated, fit patients with chronic lymphocytic leukemia: a subgroup analysis of the GREEN study. <i>Leukemia</i> , 2020, 34, 441-450.	7.2	8
61	Reconstruction of rearranged T cell receptor loci by whole genome and transcriptome sequencing gives insights into the initial steps of T cell prolymphocytic leukemia. <i>Genes Chromosomes and Cancer</i> , 2020, 59, 261-267.	2.8	16
62	Genomic alterations in high-risk chronic lymphocytic leukemia frequently affect cell cycle key regulators and NOTCH1-regulated transcription. <i>Haematologica</i> , 2020, 105, 1379-1390.	3.5	24
63	Influence of obesity and gender on treatment outcomes in patients with chronic lymphocytic leukemia (CLL) undergoing rituximab-based chemoimmunotherapy. <i>Leukemia</i> , 2020, 34, 1177-1181.	7.2	6
64	TBET-expressing Th1 CD4 <sup>+</sup> T cells accumulate in chronic lymphocytic leukaemia without affecting disease progression in <i>CLL</i> mice. <i>British Journal of Haematology</i> , 2020, 189, 133-145.	2.5	11
65	Elevated Hedgehog activity contributes to attenuated DNA damage responses in aged hematopoietic cells. <i>Leukemia</i> , 2020, 34, 1125-1134.	7.2	10
66	Integration of the B-Cell Receptor Antigen Neurabin-I/SAMD14 Into an Antibody Format as New Therapeutic Approach for the Treatment of Primary CNS Lymphoma. <i>Frontiers in Oncology</i> , 2020, 10, 580364.	2.8	3
67	Prolonged Course of COVID-19-Associated Pneumonia in a B-Cell Depleted Patient After Rituximab. <i>Frontiers in Oncology</i> , 2020, 10, 1578.	2.8	44
68	Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2020, 21, 1188-1200.	10.7	208
69	Role of Specific B-Cell Receptor Antigens in Lymphomagenesis. <i>Frontiers in Oncology</i> , 2020, 10, 604685.	2.8	11
70	DNA methylation of chronic lymphocytic leukemia with differential response to chemotherapy. <i>Scientific Data</i> , 2020, 7, 133.	5.3	6
71	Feasibility and Safety of CD19 Chimeric Antigen Receptor T Cell Treatment for B Cell Lymphoma Relapse after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1575-1580.	2.0	20
72	Prognostic and predictive impact of genetic markers in patients with CLL treated with obinutuzumab and venetoclax. <i>Blood</i> , 2020, 135, 2402-2412.	1.4	83

#	ARTICLE	IF	CITATIONS
73	International prognostic score for asymptomatic early-stage chronic lymphocytic leukemia. <i>Blood</i> , 2020, 135, 1859-1869.	1.4	86
74	Noncatalytic Bruton's tyrosine kinase activates PLC $\beta$ 2 variants mediating ibrutinib resistance in human chronic lymphocytic leukemia cells. <i>Journal of Biological Chemistry</i> , 2020, 295, 5717-5736.	3.4	20
75	Methylome-based cell-of-origin modeling (Methyl-COOM) identifies aberrant expression of immune regulatory molecules in CLL. <i>Genome Medicine</i> , 2020, 12, 29.	8.2	15
76	Approved and emerging PI3K inhibitors for the treatment of chronic lymphocytic leukemia and non-Hodgkin lymphoma. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 917-929.	1.8	23
77	Efficacy and Safety of Duvelisib Following Disease Progression on Ofatumumab in Patients with Relapsed/Refractory CLL or SLL in the DUO Crossover Extension Study. <i>Clinical Cancer Research</i> , 2020, 26, 2096-2103.	7.0	31
78	COVID-19 among fit patients with CLL treated with venetoclax-based combinations. <i>Leukemia</i> , 2020, 34, 2225-2229.	7.2	39
79	Revolution of Chronic Lymphocytic Leukemia Therapy: the Chemo-Free Treatment Paradigm. <i>Current Oncology Reports</i> , 2020, 22, 16.	4.0	22
80	Prognostic impact of prevalent chronic lymphocytic leukemia stereotyped subsets: analysis within prospective clinical trials of the German CLL Study Group (GCLLSG). <i>Haematologica</i> , 2020, 105, 2598-2607.	3.5	44
81	Early treatment with FCR versus watch and wait in patients with stage Binet A high-risk chronic lymphocytic leukemia (CLL): a randomized phase 3 trial. <i>Leukemia</i> , 2020, 34, 2038-2050.	7.2	38
82	<i>IGHV3-21</i> is an inherited risk factor for CLL through the acquisition of a single-point mutation enabling autonomous BCR signaling. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 4320-4327.	7.1	55
83	Prognostic model for newly diagnosed CLL patients in Binet stage A: results of the multicenter, prospective CLL1 trial of the German CLL study group. <i>Leukemia</i> , 2020, 34, 1038-1051.	7.2	24
84	Stromal cell protein kinase C $\beta$ inhibition enhances chemosensitivity in B cell malignancies and overcomes drug resistance. <i>Science Translational Medicine</i> , 2020, 12, .	12.4	18
85	Prognostic and predictive role of gene mutations in chronic lymphocytic leukemia: results from the pivotal phase III study COMPLEMENT1. <i>Haematologica</i> , 2020, 105, 2440-2447.	3.5	31
86	Characterization of an HLA-restricted and human cytomegalovirus-specific antibody repertoire with therapeutic potential. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 1535-1548.	4.2	2
87	High efficacy of venetoclax plus obinutuzumab in patients with complex karyotype and chronic lymphocytic leukemia. <i>Blood</i> , 2020, 135, 866-870.	1.4	30
88	<i>BIRC3</i> mutations in chronic lymphocytic leukemia are uncommon and unfavorable. <i>Haematologica</i> , 2020, 105, 255-256.	3.5	9
89	Telomere Dysfunction in Chronic Lymphocytic Leukemia. <i>Frontiers in Oncology</i> , 2020, 10, 612665.	2.8	12
90	Adjuvant Therapy of High-Risk (Stages IIC-IV) Malignant Melanoma in the Post Interferon-Alpha Era: A Systematic Review and Meta-Analysis. <i>Frontiers in Oncology</i> , 2020, 10, 637161.	2.8	15

#	ARTICLE	IF	CITATIONS
91	Fixed-duration venetoclax-obinutuzumab for previously untreated patients with chronic lymphocytic leukemia: Follow-up of efficacy and safety results from the multicenter, open-label, randomized, phase III CLL14 trial.. Journal of Clinical Oncology, 2020, 38, 8027-8027.	1.6	4
92	Robust Discovery of Candidate DNA Methylation Cancer Drivers. Blood, 2020, 136, 33-34.	1.4	0
93	Spontaneous regression of a plasmablastic lymphoma with <i>MYC</i> rearrangement. British Journal of Haematology, 2019, 186, e203-e207.	2.5	10
94	Long-Term Studies Assessing Outcomes of Ibrutinib Therapy in Patients With Del(11q) Chronic Lymphocytic Leukemia. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, 715-722.e6.	0.4	35
95	Prediction of venetoclax activity in precursor B-ALL by functional assessment of apoptosis signaling. Cell Death and Disease, 2019, 10, 571.	6.3	29
96	Effect of Dose Modifications on Response to Duvelisib in Patients with Relapsed/Refractory (R/R) CLL/SLL in the DUO Trial. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, S273-S274.	0.4	1
97	An Improved Benefit-Risk Profile of Duvelisib in Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Who Received ≥2 Prior Therapies. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, S276.	0.4	0
98	Time-to-progression after front-line fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy for chronic lymphocytic leukaemia: a retrospective, multicohort study. Lancet Oncology, The, 2019, 20, 1576-1586.	10.7	26
99	Dissecting the Prognostic Significance and Functional Role of Progranulin in Chronic Lymphocytic Leukemia. Cancers, 2019, 11, 822.	3.7	5
100	Mode of progression after first line treatment correlates with outcome of chronic lymphocytic leukemia (CLL). American Journal of Hematology, 2019, 94, 1002-1006.	4.1	5
101	Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions. New England Journal of Medicine, 2019, 380, 2225-2236.	27.0	599
102	Linking aberrant chromatin features in chronic lymphocytic leukemia to transcription factor networks. Molecular Systems Biology, 2019, 15, e8339.	7.2	39
103	Phase 1 first-in-human trial of the anti-CD37 antibody BI 836826 in relapsed/refractory chronic lymphocytic leukemia. Leukemia, 2019, 33, 2531-2535.	7.2	20
104	Venetoclax resistance and acquired <i>BCL2</i> mutations in chronic lymphocytic leukemia. Haematologica, 2019, 104, e434-e437.	3.5	144
105	IGF1R as druggable target mediating PI3K- $\hat{\imath}$ inhibitor resistance in a murine model of chronic lymphocytic leukemia. Blood, 2019, 134, 534-547.	1.4	51
106	MDM4 Is Targeted by 1q Gain and Drives Disease in Burkitt Lymphoma. Cancer Research, 2019, 79, 3125-3138.	0.9	19
107	Final Results of a Randomized, Phase III Study of Rituximab With or Without Idelalisib Followed by Open-Label Idelalisib in Patients With Relapsed Chronic Lymphocytic Leukemia. Journal of Clinical Oncology, 2019, 37, 1391-1402.	1.6	177
108	Efficacy of venetoclax in relapsed chronic lymphocytic leukemia is influenced by disease and response variables. Blood, 2019, 134, 111-122.	1.4	145

#	ARTICLE	IF	CITATIONS
109	Short telomeres are associated with inferior outcome, genomic complexity, and clonal evolution in chronic lymphocytic leukemia. <i>Leukemia</i> , 2019, 33, 2183-2194.	7.2	19
110	Genomic and transcriptomic changes complement each other in the pathogenesis of sporadic Burkitt lymphoma. <i>Nature Communications</i> , 2019, 10, 1459.	12.8	99
111	Response to Comment by Jonathan Weiss et al.. <i>Haematologica</i> , 2019, 104, e542-e542.	3.5	1
112	Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial. <i>Lancet, The</i> , 2019, 394, 2271-2281.	13.7	155
113	From Biology to Therapy: The CLL Success Story. <i>HemaSphere</i> , 2019, 3, e175.	2.7	55
114	PI3K $\gamma$ inhibition modulates regulatory and effector T-cell differentiation and function in chronic lymphocytic leukemia. <i>Leukemia</i> , 2019, 33, 1427-1438.	7.2	51
115	CLL2-BIG: sequential treatment with bendamustine, ibrutinib and obinutuzumab (GA101) in chronic lymphocytic leukemia. <i>Leukemia</i> , 2019, 33, 1161-1172.	7.2	38
116	The involvement of microRNA in the pathogenesis of Richter syndrome. <i>Haematologica</i> , 2019, 104, 1004-1015.	3.5	20
117	Prognostic value of MRD in CLL patients with comorbidities receiving chlorambucil plus obinutuzumab or rituximab. <i>Blood</i> , 2019, 133, 494-497.	1.4	32
118	FBXW7 mutations reduce binding of NOTCH1, leading to cleaved NOTCH1 accumulation and target gene activation in CLL. <i>Blood</i> , 2019, 133, 830-839.	1.4	56
119	New lessons learned in T-PLL: results from a prospective phase-II trial with fludarabine $\rightarrow$ mitoxantrone $\rightarrow$ cyclophosphamide $\rightarrow$ alemtuzumab induction followed by alemtuzumab maintenance. <i>Leukemia and Lymphoma</i> , 2019, 60, 649-657.	1.3	15
120	Control of chronic lymphocytic leukemia development by clonally-expanded CD8+ T-cells that undergo functional exhaustion in secondary lymphoid tissues. <i>Leukemia</i> , 2019, 33, 625-637.	7.2	55
121	Anti-CD20 immunotherapy as a bridge to tolerance, after allogeneic stem cell transplantation for patients with chronic lymphocytic leukaemia: results of the CLLX4 trial. <i>British Journal of Haematology</i> , 2019, 184, 833-836.	2.5	6
122	Obinutuzumab Alone or Combined with Chemotherapy in Previously Untreated (Fit or Unfit) or Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) Patients: Final Results from the Phase IIIb GREEN Safety Study with a Focus on Efficacy. <i>Blood</i> , 2019, 134, 3035-3035.	1.4	1
123	Comparison of Overall Survival in High Risk Patients with Minimal Residual Disease after First-Line Treatment across Three Generations of Phase 3 Trials of the German CLL Study Group. <i>Blood</i> , 2019, 134, 3040-3040.	1.4	1
124	Quantitative Analysis of Minimal Residual Disease (MRD) Shows High Rates of Undetectable MRD after Fixed-Duration Chemotherapy-Free Treatment and Serves As Surrogate Marker for Progression-Free Survival: A Prospective Analysis of the Randomized CLL14 Trial. <i>Blood</i> , 2019, 134, 36-36.	1.4	18
125	Primary Analysis of Anti-CD19 Tafasitamab (MOR208) Treatment in Combination with Idelalisib or Venetoclax in R/R CLL Patients Who Failed Prior BTK Inhibitor Therapy (COSMOS Trial). <i>Blood</i> , 2019, 134, 1754-1754.	1.4	7
126	Role of FDG PET/CT to Detect Bone Marrow Involvement in the Initial Staging of Aggressive Non-Hodgkin Lymphoma. <i>Blood</i> , 2019, 134, 2892-2892.	1.4	2



#	ARTICLE	IF	CITATIONS
127	Bortezomib-Based Induction and Maintenance Overcomes the Negative Prognostic Impact of Renal Impairment and del17p in Transplant-Eligible Myeloma Patients: Long Term Results from the Phase III HOVON-65/GMMG-HD4 Study after Median 137 Months Follow up. <i>Blood</i> , 2019, 134, 3308-3308.	1.4	3
128	A Prospective, Open-Label, Multicenter, Phase 2 Trial to Evaluate the Safety and Efficacy of the Combination of Tirabrutinib (ONO/GS-4059) and Entospletinib with and without Obinutuzumab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2019, 134, 4297-4297.	1.4	5
129	A Prospective, Open-Label, Multicenter, Phase 2 Trial to Evaluate the Safety and Efficacy of the Combination of Tirabrutinib (ONO/GS-4059) and Idelalisib with and without Obinutuzumab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2019, 134, 3047-3047.	1.4	3
130	Inherited DNA repair and cell cycle gene defects in chronic lymphocytic leukemia.. <i>Journal of Clinical Oncology</i> , 2019, 37, 1508-1508.	1.6	2
131	Effect of dose modifications on response to duvelisib in patients with relapsed/refractory (R/R) CLL/SLL in the DUO trial.. <i>Journal of Clinical Oncology</i> , 2019, 37, 7523-7523.	1.6	4
132	Targeted therapy in CLL: changing the treatment paradigm. <i>Oncotarget</i> , 2019, 10, 4002-4003.	1.8	3
133	CLL with Del (17p)/TP53 Mutation. <i>Hematologic Malignancies</i> , 2019, , 97-106.	0.2	0
134	Effect of fixed-duration venetoclax plus obinutuzumab (VenG) on progression-free survival (PFS), and rates and duration of minimal residual disease negativity (MRD <sup>â€</sup> ) in previously untreated patients (pts) with chronic lymphocytic leukemia (CLL) and comorbidities.. <i>Journal of Clinical Oncology</i> , 2019, 37, 7502-7502.	1.6	1
135	Eomes and IL-10 Regulate Anti-Tumor Activity of T Cells in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2019, 134, 4288-4288.	1.4	0
136	Modelling Single Cell B-Cell Receptor Signaling Reveals Enhanced Activity in Primary CLL Cells Compared to Non-Malignant Cells While Fundamental Network Circuit Topology Remains Stable Even with Novel Therapeutic Inhibitors. <i>Blood</i> , 2019, 134, 4275-4275.	1.4	0
137	Venetoclax Resistance in Mantle Cell Lymphoma Is Mediated By BCL-XL and Can be Circumvent By Inhibiting the BH4 Domain of BCL-2. <i>Blood</i> , 2019, 134, 1507-1507.	1.4	1
138	The B-Cell Receptor Antigen ARS2 Can be Integrated into a BAR-Body Format to Treat Diffuse Large B-Cell Lymphomas in Xenograft Mouse Models. <i>Blood</i> , 2019, 134, 2860-2860.	1.4	0
139	Identification and Characterization of CMV-Specific, HLA-C*07:02 Restricted Antibodies. <i>Blood</i> , 2019, 134, 5616-5616.	1.4	0
140	Telomere Shortening By Terc Knockout in the E $\mu$ -TCL1 Transgenic Murine Model of CLL: Characterization of Disease Development and Survival. <i>Blood</i> , 2019, 134, 1732-1732.	1.4	0
141	Characterization of Mechanisms of Acquired Venetoclax-Insensitivity in B-Cell Precursor Acute Lymphoblastic Leukemia. <i>Blood</i> , 2019, 134, 3954-3954.	1.4	0
142	Optimising outcomes for patients with chronic lymphocytic leukaemia on ibrutinib therapy: European recommendations for clinical practice. <i>British Journal of Haematology</i> , 2018, 180, 666-679.	2.5	51
143	Tumor necrosis factor receptor signaling is a driver of chronic lymphocytic leukemia that can be therapeutically targeted by the flavonoid wogonin. <i>Haematologica</i> , 2018, 103, 688-697.	3.5	26
144	iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. <i>Blood</i> , 2018, 131, 2745-2760.	1.4	1,069

#	ARTICLE	IF	CITATIONS
145	CLL2-BXX Phase II trials: sequential, targeted treatment for eradication of minimal residual disease in chronic lymphocytic leukemia. <i>Future Oncology</i> , 2018, 14, 499-513.	2.4	27
146	Telomere length in poor-risk chronic lymphocytic leukemia: associations with disease characteristics and outcome. <i>Leukemia and Lymphoma</i> , 2018, 59, 1614-1623.	1.3	12
147	<i>NFATC1</i> activation by <i>DNA</i> hypomethylation in chronic lymphocytic leukemia correlates with clinical staging and can be inhibited by ibrutinib. <i>International Journal of Cancer</i> , 2018, 142, 322-333.	5.1	33
148	Venetoclax for Patients With Chronic Lymphocytic Leukemia With 17p Deletion: Results From the Full Population of a Phase II Pivotal Trial. <i>Journal of Clinical Oncology</i> , 2018, 36, 1973-1980.	1.6	257
149	<i>TP53</i> aberrations in chronic lymphocytic leukemia: an overview of the clinical implications of improved diagnostics. <i>Haematologica</i> , 2018, 103, 1956-1968.	3.5	94
150	Outcome of patients aged 80 years or older treated for chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2018, 183, 727-735.	2.5	7
151	The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL. <i>Blood</i> , 2018, 132, 2446-2455.	1.4	261
152	IG-MYC+ neoplasms with precursor B-cell phenotype are molecularly distinct from Burkitt lymphomas. <i>Blood</i> , 2018, 132, 2280-2285.	1.4	50
153	Venetoclax: Targeting BCL2 in Hematological Cancers. <i>Recent Results in Cancer Research</i> , 2018, 212, 215-242.	1.8	25
154	Safety of obinutuzumab alone or combined with chemotherapy for previously untreated or relapsed/refractory chronic lymphocytic leukemia in the phase IIIb GREEN study. <i>Haematologica</i> , 2018, 103, 1889-1898.	3.5	19
155	High-risk chronic lymphocytic leukemia in the era of pathway inhibitors: integrating molecular and cellular therapies. <i>Blood</i> , 2018, 132, 892-902.	1.4	83
156	Obinutuzumab plus bendamustine in previously untreated patients with CLL: a subgroup analysis of the GREEN study. <i>Leukemia</i> , 2018, 32, 1778-1786.	7.2	28
157	Bendamustine followed by obinutuzumab and venetoclax in chronic lymphocytic leukaemia (CLL2-BAG): primary endpoint analysis of a multicentre, open-label, phase 2 trial. <i>Lancet Oncology</i> , 2018, 19, 1215-1228.	10.7	94
158	Evaluation of 230 patients with relapsed/refractory deletion 17p chronic lymphocytic leukaemia treated with ibrutinib from 3 clinical trials. <i>British Journal of Haematology</i> , 2018, 182, 504-512.	2.5	37
159	Comprehensive Safety Analysis of Venetoclax Monotherapy for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia. <i>Clinical Cancer Research</i> , 2018, 24, 4371-4379.	7.0	127
160	Minimal Residual Disease Status with Venetoclax Monotherapy Is Associated with Progression-Free Survival in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2018, 132, 3134-3134.	1.4	5
161	Excellent Outcome of Young Patients (18-60 years) with Favourable-Prognosis Diffuse Large B-Cell Lymphoma (DLBCL) Treated with 4 Cycles CHOP Plus 6 Applications of Rituximab: Results of the 592 Patients of the Flyer Trial of the Dshnhl/GLA. <i>Blood</i> , 2018, 132, 781-781.	1.4	14
162	Durable Remissions after Discontinuation of Combined Targeted Treatment in Patients with Chronic Lymphocytic Leukemia (CLL) Harboring a High-Risk Genetic Lesion (del(17p)/TP53 Mutation). <i>Blood</i> , 2018, 132, 694-694.	1.4	16

#	ARTICLE	IF	CITATIONS
163	Residual Abdominal Lymphadenopathy after Intensive Frontline Chemoimmunotherapy Is Associated with Inferior Outcome Regardless of MRD Status in Advanced Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2018, 132, 4430-4430.	1.4	1
164	Identification of Posttranslationally Modified Neoantigens As Targets of B Cell Receptors of Burkitt Lymphoma. <i>Blood</i> , 2018, 132, 1588-1588.	1.4	2
165	Clinical and Biological Indicators of Duvelisib Efficacy in CLL from the Phase 3 DUOTM Study. <i>Blood</i> , 2018, 132, 1856-1856.	1.4	2
166	Hypophosphatemia after High Dosage Iron Substitution with Ferric Carboxymaltose (FCM) and Iron Isomaltoside (IM) in the Randomised Controlled Home Affairs 1 Trial. <i>Blood</i> , 2018, 132, 3627-3627.	1.4	5
167	Two-Cohort Phase II Study in R/R CLL (COSMOS): First Preliminary Safety and Efficacy Results of Anti-CD19 MOR208 Treatment in Combination with Venetoclax in Patients Who Discontinued Prior BTK Inhibitor Therapy. <i>Blood</i> , 2018, 132, 4433-4433.	1.4	2
168	NOTCH1 Signaling Is Activated in CLL By Mutations of FBXW7 and Low Expression of USP28 at 11q23. <i>Blood</i> , 2018, 132, 946-946.	1.4	1
169	Vecabrutinib Is Efficacious In Vivo in a Preclinical CLL Adoptive Transfer Model. <i>Blood</i> , 2018, 132, 1868-1868.	1.4	1
170	The Efficacy and Safety of Duvelisib Following Disease Progression on Ofatumumab in Patients with Relapsed/Refractory CLL or SLL: Updated Results from the DUO Crossover Extension Study. <i>Blood</i> , 2018, 132, 3140-3140.	1.4	2
171	Safety and Efficacy of Venetoclax (VEN) in Combination with Bendamustine (B) Plus Rituximab (R) or Obinutuzumab (G) in Patients (pts) with Previously Untreated Chronic Lymphocytic Leukemia (CLL): Results from a Phase Ib Study (GO28440). <i>Blood</i> , 2018, 132, 1859-1859.	1.4	1
172	Duvelisib inhibition of chemokines in patients with CLL (DUO study) and iNHL (DYNAMO study).. <i>Journal of Clinical Oncology</i> , 2018, 36, 12048-12048.	1.6	2
173	The efficacy of duvelisib monotherapy following disease progression on ofatumumab monotherapy in patients with relapsed/refractory CLL or SLL in the DUO crossover extension study.. <i>Journal of Clinical Oncology</i> , 2018, 36, 7533-7533.	1.6	1
174	The GAIA (CLL13) trial: An international intergroup phase III study for frontline therapy in chronic lymphocytic leukemia (CLL).. <i>Journal of Clinical Oncology</i> , 2018, 36, TPS7582-TPS7582.	1.6	7
175	A phase 1, open-label, multicenter, non-randomized study to assess the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of AZD4573, a potent and selective CDK9 inhibitor, in subjects with relapsed or refractory hematological malignancies.. <i>Journal of Clinical Oncology</i> , 2018, 36, TPS7588-TPS7588.	1.6	6
176	Functional characterization of phospholipase C- $\beta$ 2 mutant protein causing both somatic ibrutinib resistance and a germline monogenic autoinflammatory disorder. <i>Oncotarget</i> , 2018, 9, 34357-34378.	1.8	14
177	B-cell acute lymphoblastic leukemia (B-ALL) in CLL patients treated with lenalidomide.. <i>Journal of Clinical Oncology</i> , 2018, 36, 7531-7531.	1.6	0
178	Comparison of different phase II studies using sequential combinations of targeted agents for treating chronic lymphocytic leukemia.. <i>Journal of Clinical Oncology</i> , 2018, 36, 7513-7513.	1.6	0
179	Prognostic role of beta-2 microglobulin (B2M) in relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) patients (pts) treated with ibrutinib (ibr).. <i>Journal of Clinical Oncology</i> , 2018, 36, 7521-7521.	1.6	0
180	Mitigation of tumor lysis syndrome (TLS) complications with venetoclax (VEN) in CLL.. <i>Journal of Clinical Oncology</i> , 2018, 36, 7526-7526.	1.6	1

#	ARTICLE	IF	CITATIONS
181	Gene Set Enrichment Analysis Suggests That Increased Rituximab-Mediated NK Cell Cytotoxicity after Vitamin D Substitution Is Driven By Upregulation of Interferon Alpha (IFN- $\alpha$ ) Isoforms. <i>Blood</i> , 2018, 132, 3696-3696.	1.4	0
182	Integrated Proteomic and Phosphoproteomic Analysis Reveal Novel Targets and Suggest Rationale for Ibrutinib Efficacy in UM-CLL. <i>Blood</i> , 2018, 132, 583-583.	1.4	0
183	Modeling of the Epigenome of the Cell-of-Origin Identifies Cancer-Specific DNA Methylation Patterns in CLL. <i>Blood</i> , 2018, 132, 3885-3885.	1.4	0
184	Obesity Negatively Impacts Outcome in Female Patients with Chronic Lymphocytic Leukemia (CLL) Treated with Fludarabine, Cyclophosphamide and Rituximab (FCR): An Analysis of Three Phase III Studies of the German CLL Study Group (GCLLSG). <i>Blood</i> , 2018, 132, 4429-4429.	1.4	0
185	MYC Pathway Activation Is Frequently Observed in Treatment-Naive CLL and Defines a Subgroup with Particular Benefit from the Addition of Rituximab to Chemotherapy. <i>Blood</i> , 2018, 132, 1866-1866.	1.4	0
186	Characterization of Mechanisms Underlying Acquired Venetoclax-Resistance in Mantle Cell Lymphoma: BDA-366 As a Potential Treatment Option. <i>Blood</i> , 2018, 132, 1580-1580.	1.4	0
187	BAR-Bodies: B-Cell Receptor Antigens As the Targeting Moiety of Antibodies in Substitution for the Variable Region of Heavy and Light Chains. <i>Blood</i> , 2018, 132, 2940-2940.	1.4	1
188	Associations of ofatumumab exposure and treatment outcomes in patients with untreated CLL receiving chemoimmunotherapy. <i>Leukemia and Lymphoma</i> , 2017, 58, 348-356.	1.3	3
189	Venetoclax in Patients with Previously Treated Chronic Lymphocytic Leukemia. <i>Clinical Cancer Research</i> , 2017, 23, 4527-4533.	7.0	56
190	Front-line treatment of CLL in the era of novel agents. <i>Cancer Treatment Reviews</i> , 2017, 53, 70-78.	7.7	25
191	Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial. <i>Lancet Oncology</i> , The, 2017, 18, 297-311.	10.7	219
192	Human NACHT, LRR, and PYD domain-containing protein 3 (NLRP3) inflammasome activity is regulated by and potentially targetable through Bruton tyrosine kinase. <i>Journal of Allergy and Clinical Immunology</i> , 2017, 140, 1054-1067.e10.	2.9	105
193	Chronic Lymphocytic Leukemia with Mutated IGHV4-34 Receptors: Shared and Distinct Immunogenetic Features and Clinical Outcomes. <i>Clinical Cancer Research</i> , 2017, 23, 5292-5301.	7.0	27
194	Immunoglobulin genes in chronic lymphocytic leukemia: key to understanding the disease and improving risk stratification. <i>Haematologica</i> , 2017, 102, 968-971.	3.5	28
195	<i>TP53</i> mutation and survival in aggressive B cell lymphoma. <i>International Journal of Cancer</i> , 2017, 141, 1381-1388.	5.1	69
196	Ibrutinib-resistant CLL: unwanted and unwonted!. <i>Blood</i> , 2017, 129, 1407-1409.	1.4	5
197	Venetoclax and obinutuzumab in chronic lymphocytic leukemia. <i>Blood</i> , 2017, 129, 2702-2705.	1.4	108
198	Impact of telomere length on the outcome of allogeneic stem cell transplantation for poor-risk chronic lymphocytic leukaemia: results from the GCLLSG CLL-3X trial. <i>British Journal of Haematology</i> , 2017, 179, 342-346.	2.5	2

#	ARTICLE	IF	CITATIONS
199	Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial. <i>Lancet Haematology</i> ,the, 2017, 4, e510-e523.	4.6	258
200	Analysis of ITGB2 rare germ line variants in chronic lymphocytic leukemia. <i>Blood</i> , 2017, 130, 2443-2444.	1.4	6
201	Tumor-derived exosomes modulate PD-L1 expression in monocytes. <i>Science Immunology</i> , 2017, 2, .	11.9	236
202	Lenalidomide maintenance after first-line therapy for high-risk chronic lymphocytic leukaemia (CLLM1): final results from a randomised, double-blind, phase 3 study. <i>Lancet Haematology</i> ,the, 2017, 4, e475-e486.	4.6	45
203	Allogeneic hematopoietic cell transplantation for high-risk CLL: 10-year follow-up of the GCLLSC CLL3X trial. <i>Blood</i> , 2017, 130, 1477-1480.	1.4	63
204	Two mouse models reveal an actionable PARP1 dependence in aggressive chronic lymphocytic leukemia. <i>Nature Communications</i> , 2017, 8, 153.	12.8	39
205	Rapid detection of ATM/p53 function with p27Kip FACS analysis: a novel diagnostic tool for chronic lymphocytic leukemia?. <i>Leukemia and Lymphoma</i> , 2017, 58, 6-7.	1.3	2
206	Alemtuzumab consolidation in chronic lymphocytic leukaemia: a phase I/II multicentre trial. <i>European Journal of Haematology</i> , 2017, 98, 254-262.	2.2	9
207	Profile of venetoclax and its potential in the context of treatment of relapsed or refractory chronic lymphocytic leukemia. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 645-656.	2.0	8
208	Chronic Lymphocytic Leukemia With TP53 Aberrations: Breakthroughs and Challenges. <i>Journal of Oncology Practice</i> , 2017, 13, 381-382.	2.5	1
209	COSMOS: MOR208 plus idelalisib or venetoclax in patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) previously treated with a Bruton's tyrosine kinase inhibitor (BTKi)â€™A two-cohort phase II study.. <i>Journal of Clinical Oncology</i> , 2017, 35, TPS7567-TPS7567.	1.6	0
210	Telomere dysfunction and chromothripsis. <i>International Journal of Cancer</i> , 2016, 138, 2905-2914.	5.1	42
211	Bendamustine and rituximab in combination with lenalidomide in patients with chronic lymphocytic leukemia. <i>European Journal of Haematology</i> , 2016, 97, 253-260.	2.2	19
212	Alterations of microRNA and microRNA-regulated messenger RNA expression in germinal center B-cell lymphomas determined by integrative sequencing analysis. <i>Haematologica</i> , 2016, 101, 1380-1389.	3.5	43
213	Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study. <i>Lancet Oncology</i> , The, 2016, 17, 768-778.	10.7	676
214	First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial. <i>Lancet Oncology</i> , The, 2016, 17, 928-942.	10.7	529
215	Prognostic Value of Ki-67 Index, Cytology, and Growth Pattern in Mantle-Cell Lymphoma: Results From Randomized Trials of the European Mantle Cell Lymphoma Network. <i>Journal of Clinical Oncology</i> , 2016, 34, 1386-1394.	1.6	276
216	Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial. <i>Lancet Haematology</i> ,the, 2016, 3, e217-e227.	4.6	442

#	ARTICLE	IF	CITATIONS
217	Safety and efficacy of different lenalidomide starting doses in patients with relapsed or refractory chronic lymphocytic leukemia: results of an international multicenter double-blinded randomized phase II trial*. <i>Leukemia and Lymphoma</i> , 2016, 57, 1291-1299.	1.3	17
218	Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial. <i>Blood</i> , 2016, 127, 208-215.	1.4	571
219	Complex karyotypes and KRAS and POT1 mutations impact outcome in CLL after chlorambucil-based chemotherapy or chemoimmunotherapy. <i>Blood</i> , 2016, 128, 395-404.	1.4	112
220	Postibrutinib outcomes in patients with mantle cell lymphoma. <i>Blood</i> , 2016, 127, 1559-1563.	1.4	228
221	High-dose chemotherapy with autologous haemopoietic stem cell transplantation for newly diagnosed primary CNS lymphoma: a prospective, single-arm, phase 2 trial. <i>Lancet Haematology</i> , 2016, 3, e388-e397.	4.6	128
222	Clinical Practice Recommendations for Use of Allogeneic Hematopoietic Cell Transplantation in Chronic Lymphocytic Leukemia on Behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 2117-2125.	2.0	87
223	Minimal Residual Disease Assessment Improves Prediction of Outcome in Patients With Chronic Lymphocytic Leukemia (CLL) Who Achieve Partial Response: Comprehensive Analysis of Two Phase III Studies of the German CLL Study Group. <i>Journal of Clinical Oncology</i> , 2016, 34, 3758-3765.	1.6	142
224	Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study. <i>Lancet Oncology</i> , 2016, 17, 1409-1418.	10.7	290
225	The Phospholipase C $\beta$ 2 Mutants R665W and L845F Identified in Ibrutinib-resistant Chronic Lymphocytic Leukemia Patients Are Hypersensitive to the Rho GTPase Rac2 Protein. <i>Journal of Biological Chemistry</i> , 2016, 291, 22136-22148.	3.4	42
226	Telomere shortening leads to an acceleration of synucleinopathy and impaired microglia response in a genetic mouse model. <i>Acta Neuropathologica Communications</i> , 2016, 4, 87.	5.2	40
227	Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network. <i>Lancet</i> , 2016, 388, 565-575.	13.7	328
228	Kruppel-like factor 4 (KLF4) inactivation in chronic lymphocytic leukemia correlates with promoter DNA-methylation and can be reversed by inhibition of NOTCH signaling. <i>Haematologica</i> , 2016, 101, e249-e253.	3.5	26
229	Efficacy of antineoplastic treatment is associated with the use of antibiotics that modulate intestinal microbiota. <i>Oncotarget</i> , 2016, 5, e1150399.	4.6	94
230	DNA methylation dynamics during B cell maturation underlie a continuum of disease phenotypes in chronic lymphocytic leukemia. <i>Nature Genetics</i> , 2016, 48, 253-264.	21.4	254
231	Genomic Features: Impact on Pathogenesis and Treatment of Chronic Lymphocytic Leukemia. <i>Oncology Research and Treatment</i> , 2016, 39, 34-40.	1.2	5
232	Evaluation of geriatric assessment in patients with chronic lymphocytic leukemia: Results of the CLL9 trial of the German CLL study group. <i>Leukemia and Lymphoma</i> , 2016, 57, 789-796.	1.3	87
233	In Vivo modeling of Resistance to PI3K $\gamma$ Inhibitor Treatment Using E $\mu$ TCL1-Tg Tumor Transfer Model. <i>Blood</i> , 2016, 128, 190-190.	1.4	7
234	Outcome of Patients with Complex Karyotype in a Phase 3 Randomized Study of Idelalisib Plus Rituximab for Relapsed Chronic Lymphocytic Leukemia. <i>Blood</i> , 2016, 128, 192-192.	1.4	11

#	ARTICLE	IF	CITATIONS
235	11q Deletion (del11q) Is Not a Prognostic Factor for Adverse Outcomes for Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Treated with Ibrutinib: Pooled Data from 3 Randomized Phase 3 Studies. <i>Blood</i> , 2016, 128, 2042-2042.	1.4	9
236	Low Incidence of Tumor Lysis Syndromes (TLS) and Infusion Related Reactions (IRR) in the CLL2-Bag Trial Evaluating a Sequential Treatment of Bendamustine (B), Obinutuzumab (GA101, G) and Venetoclax (ABT-199, A) in Patients with Chronic Lymphocytic Leukemia (CLL): Interim Safety Results of a Phase-II-Trial of the German CLL Study Group (GCLLSG). <i>Blood</i> , 2016, 128, 2044-2044.	1.4	4
237	Safety and Efficacy of Venetoclax and Obinutuzumab in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL) and Coexisting Medical Conditions: Final Results of the Run-in Phase of the Randomized CLL14 Trial (BO25323). <i>Blood</i> , 2016, 128, 2054-2054.	1.4	8
238	Lenalidomide Maintenance after Front Line Therapy Substantially Prolongs Progression Free Survival in High Risk CLL: Interim Results of a Phase 3 Study (CLL M1 study of the German CLL Study Group). <i>Blood</i> , 2016, 128, 229-229.	1.4	12
239	Updated Analysis of Overall Survival in Randomized Phase III Study of Idelalisib in Combination with Bendamustine and Rituximab in Patients with Relapsed/Refractory CLL. <i>Blood</i> , 2016, 128, 231-231.	1.4	4
240	Whole-Exome Sequencing Revealed No Recurrent Mutations within the PI3K Pathway in Relapsed Chronic Lymphocytic Leukemia Patients Progressing Under Idelalisib Treatment. <i>Blood</i> , 2016, 128, 2770-2770.	1.4	26
241	CLL Exosome-Derived Y RNA hY4 Induces TLR7/8-Mediated Inflammation and PD-L1 Expression in Monocytes. <i>Blood</i> , 2016, 128, 3217-3217.	1.4	1
242	Gene Mutations and Treatment Outcome in the Context of Chlorambucil (Clb) without or with the Addition of Rituximab (R) or Obinutuzumab (GA-101, G) - Results of an Extensive Analysis of the Phase III Study CLL11 of the German CLL Study Group. <i>Blood</i> , 2016, 128, 3227-3227.	1.4	19
243	Pooled Multi-Trial Analysis of Venetoclax Efficacy in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia. <i>Blood</i> , 2016, 128, 3230-3230.	1.4	12
244	Reappraising Immunoglobulin Repertoire Restrictions in Chronic Lymphocytic Leukemia: Focus on Major Stereotyped Subsets and Closely Related Satellites. <i>Blood</i> , 2016, 128, 4376-4376.	1.4	1
245	Favorable Toxicity Profile and Long Term Outcome of Elderly, but Physically Fit CLL Patients (pts) Receiving First Line Bendamustine and Rituximab (BR) Frontline Chemoimmunotherapy in Comparison to Fludarabine, Cyclophosphamide, and Rituximab (FCR) in Advanced Chronic Lymphocytic Leukemia (CLL): Update Analysis of an International, Randomized Study of the German CLL Study Group (GCLLSG) (CLL10 Study). <i>Blood</i> , 2016, 128, 4382-4382.	1.4	11
246	Phase Ib Study (GO28440) of Venetoclax with Bendamustine/Rituximab or Bendamustine/Obinutuzumab in Patients with Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia. <i>Blood</i> , 2016, 128, 4393-4393.	1.4	17
247	Safety Profile of Venetoclax Monotherapy in Patients with Chronic Lymphocytic Leukemia. <i>Blood</i> , 2016, 128, 4395-4395.	1.4	7
248	Evaluation of the International Prognostic Index for Chronic Lymphocytic Leukemia (CLL-IPI) in Elderly Patients with Comorbidities: Analysis of the CLL11 Study Population. <i>Blood</i> , 2016, 128, 4401-4401.	1.4	9
249	Effects on Survival and Neurocognitive Functions of Whole-Brain Radiotherapy (WBRT) and Autologous Stem Cell Transplantation (ASCT) as Consolidation Options after High-Dose Methotrexate-Based Chemoimmunotherapy in Patients with Newly Diagnosed Primary CNS Lymphoma (PCNSL): Results of the Second Randomization of the IELSG32 Trial. <i>Blood</i> , 2016, 128, 511-511.	1.4	13
250	CLL2-BIG - a Novel Treatment Regimen of Bendamustine Followed By GA101 and Ibrutinib Followed By Ibrutinib and GA101 Maintenance in Patients with Chronic Lymphocytic Leukemia (CLL): Results of a Phase II-Trial. <i>Blood</i> , 2016, 128, 640-640.	1.4	9
251	Long-Term Outcome of Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for Chronic Lymphocytic Leukemia (CLL): 10-Year Follow-up of the Gcllsg CLL3X Trial. <i>Blood</i> , 2016, 128, 682-682.	1.4	3
252	In Chronic Lymphocytic Leukemia $\hat{I}$ CT7544-7545 Mutant NOTCH1 Maintains Transcription Factor Activity with Longer Lasting Effects Due to Slower Degradation. <i>Blood</i> , 2016, 128, 971-971.	1.4	8

#	ARTICLE	IF	CITATIONS
253	High-Dose Chemotherapy with Autologous Hematopoietic Stem Cell Support for Relapsed or Refractory Primary CNS Lymphoma - a Prospective Multicentre Trial By the German Cooperative PCNSL Study Group. <i>Blood</i> , 2016, 128, 781-781.	1.4	0
254	Impact of Gender on Outcome after Chemoimmunotherapy with Fludarabine, Cyclophosphamide and Rituximab (FCR) or Bendamustine Plus Rituximab (BR) in Patients with Chronic Lymphocytic Leukemia (CLL): A Meta-Analysis of Three Phase II/III Studies of the German CLL Study Group (GCLLSG). <i>Blood</i> , 2016, 128, 4394-4394.	1.4	1
255	Anti-Leukemia Activity of the Selective BCL-2 Inhibitor ABT-199 in Childhood B-Cell Precursor Acute Lymphoblastic Leukemia Is Characterized By MCL-1/BCL-2 Expression Serving As Biomarker for Treatment Response. <i>Blood</i> , 2016, 128, 1081-1081.	1.4	10
256	Assessment of Measures to Reduce Infusion-Related Reactions in Patients with Chronic Lymphocytic Leukemia Treated with Obinutuzumab in the GREEN Study. <i>Blood</i> , 2016, 128, 5589-5589.	1.4	0
257	Prognostic markers and standard management of chronic lymphocytic leukemia. <i>Hematology American Society of Hematology Education Program</i> , 2015, 2015, 368-377.	2.5	29
258	Targeting inhibitor of apoptosis proteins by <sc>S</sc>mac mimetic elicits cell death in poor prognostic subgroups of chronic lymphocytic leukemia. <i>International Journal of Cancer</i> , 2015, 137, 2959-2970.	5.1	17
259	Management of Chronic Lymphocytic Leukemia. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2015, , 164-175.	3.8	24
260	Epigenetic silencing of miR-708 enhances NF- $\kappa$ B signaling in chronic lymphocytic leukemia. <i>International Journal of Cancer</i> , 2015, 137, 1352-1361.	5.1	52
261	How best to manage patients with chronic lymphocytic leukemia with 17p deletion and/or TP53 mutation?. <i>Leukemia and Lymphoma</i> , 2015, 56, 587-593.	1.3	18
262	Ofatumumab in poor-prognosis chronic lymphocytic leukemia: a Phase IV, non-interventional, observational study from the European Research Initiative on Chronic Lymphocytic Leukemia. <i>Haematologica</i> , 2015, 100, 511-516.	3.5	42
263	Final results of EFC6663: A multicenter, international, phase 2 study of alvocidib for patients with fludarabine-refractory chronic lymphocytic leukemia. <i>Leukemia Research</i> , 2015, 39, 495-500.	0.8	46
264	Ofatumumab monotherapy in fludarabine-refractory chronic lymphocytic leukemia: final results from a pivotal study. <i>Haematologica</i> , 2015, 100, e311-4.	3.5	15
265	Mutations driving CLL and their evolution in progression and relapse. <i>Nature</i> , 2015, 526, 525-530.	27.8	868
266	Obinutuzumab (GA101) for the Treatment of Chronic Lymphocytic Leukemia and Other B-Cell Non-Hodgkin's Lymphomas: A Glycoengineered Type II CD20 Antibody. <i>Oncology Research and Treatment</i> , 2015, 38, 185-192.	1.2	49
267	The CLL12 trial protocol: a placebo-controlled double-blind Phase III study of ibrutinib in the treatment of early-stage chronic lymphocytic leukemia patients with risk of early disease progression. <i>Future Oncology</i> , 2015, 11, 1895-1903.	2.4	34
268	MINCR is a MYC-induced lncRNA able to modulate MYC's transcriptional network in Burkitt lymphoma cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, E5261-70.	7.1	91
269	Outcome of advanced chronic lymphocytic leukemia following different first-line and relapse therapies: a meta-analysis of five prospective trials by the German CLL Study Group (GCLLSG). <i>Haematologica</i> , 2015, 100, 1451-1459.	3.5	34
270	Loss of cooperativity of secreted CD40L and increased dose-response to IL4 on CLL cell viability correlates with enhanced activation of NF- $\kappa$ B and STAT6. <i>International Journal of Cancer</i> , 2015, 136, 65-73.	5.1	11



#	ARTICLE	IF	CITATIONS
271	Progressive Epigenetic Programming during B Cell Maturation Is Reflected in a Continuum of Epigenetic Disease Phenotypes in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2015, 126, 2436-2436.	1.4	1
272	Ibrutinib in Early Stage CLL: Preliminary Safety Results of a Placebo-Controlled Phase III Study. <i>Blood</i> , 2015, 126, 2934-2934.	1.4	6
273	Quantitative Clonal Dynamics Define Mechanisms of CLL Evolution in Response to Combination Chemotherapy. <i>Blood</i> , 2015, 126, 362-362.	1.4	4
274	CLL2-BIG - a Novel Treatment Regimen of Bendamustine Followed By GA101 and Ibrutinib Followed By Ibrutinib and GA101 Maintenance in Patients with Chronic Lymphocytic Leukemia (CLL): Interim Results of a Phase II-Trial. <i>Blood</i> , 2015, 126, 4151-4151.	1.4	8
275	Prognostic Impact and Risk Factors of Reducing Prescribed Doses of Fludarabine, Cyclophosphamide and Rituximab (FCR) during Frontline Treatment of Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2015, 126, 4156-4156.	1.4	12
276	Safety and Efficacy of Obinutuzumab Plus Bendamustine in Previously Untreated Patients with Chronic Lymphocytic Leukemia: Subgroup Analysis of the Green Study. <i>Blood</i> , 2015, 126, 493-493.	1.4	12
277	Results of the Safety Run-in Phase of CLL14 (BO25323): A Prospective, Open-Label, Multicenter Randomized Phase III Trial to Compare the Efficacy and Safety of Obinutuzumab and Venetoclax (GDC-0199/ABT-199) with Obinutuzumab and Chlorambucil in Patients with Previously Untreated CLL and Coexisting Medical Conditions. <i>Blood</i> , 2015, 126, 496-496.	1.4	17
278	Lenalidomide Exhibits Activity in Mantle Cell Lymphoma through Increased NK Cell Mediated Cytotoxicity. <i>Blood</i> , 2015, 126, 821-821.	1.4	1
279	Updated Safety and Preliminary Efficacy Data from a Phase 1b Study Combining Venetoclax (GDC-0199,) Tj ETQq1 1 0.784314 rgBT / 0 Chronic Lymphocytic Leukemia. <i>Blood</i> , 2015, 126, 829-829.	1.4	6
280	Outcome of Ibrutinib Treatment by Baseline Genetic Features in Patients with Relapsed or Refractory CLL/SLL with del17p in the Resonate-17 Study. <i>Blood</i> , 2015, 126, 833-833.	1.4	15
281	Targeting Mutant p53 in Pediatric Acute Lymphoblastic Leukemia. <i>Blood</i> , 2015, 126, 903-903.	1.4	1
282	E $\mu$ -TCL1mTerc <sup>-/-</sup> Mouse Model for Telomere Dysfunction in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2015, 126, 1724-1724.	1.4	0
283	Genomic Disruption of the Histone Methyltransferase SETD2 in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2015, 126, 365-365.	1.4	0
284	Microenvironmental Stromal Cells Rescue CLL Cells from Apoptosis Via Hypoxia That Can be Targeted Therapeutically. <i>Blood</i> , 2015, 126, 4140-4140.	1.4	0
285	CLL with Mutated IGHV4-34 Antigen Receptors Is Clinically Heterogeneous: Antigen Receptor Stereotypy Makes the Difference. <i>Blood</i> , 2015, 126, 5263-5263.	1.4	0
286	Idelalisib Treatment Is Associated with Improved Cytopenias in Patients with Relapsed/Refractory iNHL and CLL. <i>Blood</i> , 2015, 126, 1747-1747.	1.4	0
287	Poor efficacy and tolerability of <sc>R $\hat{e}$ CHOP</sc> in relapsed/refractory chronic lymphocytic leukemia and <sc>R</sc>ichter transformation. <i>American Journal of Hematology</i> , 2014, 89, E239-43.	4.1	81
288	Assessment of <sc>TP</sc>53 functionality in chronic lymphocytic leukaemia by different assays; an <sc>ERIC</sc>-wide approach. <i>British Journal of Haematology</i> , 2014, 167, 565-569.	2.5	7

#	ARTICLE	IF	CITATIONS
289	Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia. <i>New England Journal of Medicine</i> , 2014, 370, 997-1007.	27.0	1,535
290	Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions. <i>New England Journal of Medicine</i> , 2014, 370, 1101-1110.	27.0	1,284
291	Development of a comprehensive prognostic index for patients with chronic lymphocytic leukemia. <i>Blood</i> , 2014, 124, 49-62.	1.4	244
292	Prognostic and Predictive Factors in Patients With Chronic Lymphocytic Leukemia: Relevant in the Era of Novel Treatment Approaches?. <i>Journal of Clinical Oncology</i> , 2014, 32, 869-872.	1.6	45
293	Resistance Mechanisms for the Bruton's Tyrosine Kinase Inhibitor Ibrutinib. <i>New England Journal of Medicine</i> , 2014, 370, 2286-2294.	27.0	1,042
294	Confirmation of the Mantle-Cell Lymphoma International Prognostic Index in Randomized Trials of the European Mantle-Cell Lymphoma Network. <i>Journal of Clinical Oncology</i> , 2014, 32, 1338-1346.	1.6	137
295	Evolution of DNA Methylation Is Linked to Genetic Aberrations in Chronic Lymphocytic Leukemia. <i>Cancer Discovery</i> , 2014, 4, 348-361.	9.4	135
296	Interactions between comorbidity and treatment of chronic lymphocytic leukemia: results of German Chronic Lymphocytic Leukemia Study Group trials. <i>Haematologica</i> , 2014, 99, 1095-1100.	3.5	101
297	MDM2 promotor polymorphism and disease characteristics in chronic lymphocytic leukemia: results of an individual patient data-based meta-analysis. <i>Haematologica</i> , 2014, 99, 1285-1291.	3.5	2
298	Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial. <i>Blood</i> , 2014, 123, 3247-3254.	1.4	428
299	PTK2 expression and immunochemotherapy outcome in chronic lymphocytic leukemia. <i>Blood</i> , 2014, 124, 420-425.	1.4	14
300	Managing high-risk CLL during transition to a new treatment era: stem cell transplantation or novel agents?. <i>Blood</i> , 2014, 124, 3841-3849.	1.4	185
301	Frontline Chemoimmunotherapy with Fludarabine (F), Cyclophosphamide (C), and Rituximab (R) (FCR) Shows Superior Efficacy in Comparison to Bendamustine (B) and Rituximab (BR) in Previously Untreated and Physically Fit Patients (pts) with Advanced Chronic Lymphocytic Leukemia (CLL): Final Analysis of an International, Randomized Study of the German CLL Study Group (GCLLSG) (CLL10 Study). <i>Blood</i> , 2014, 124, 19-19.	1.4	62
302	Subclonal Driver Mutations Predict Shorter Progression Free Survival in Chronic Lymphocytic Leukemia Following First-Line Chemo(immuno)Therapy: Results from the CLL8 Trial. <i>Blood</i> , 2014, 124, 1938-1938.	1.4	4
303	Alemtuzumab Combined with Dexamethasone, Followed By Alemtuzumab Maintenance or Allo-SCT in "œltra High-risk" CLL: Final Results from the CLL20 Phase II Study. <i>Blood</i> , 2014, 124, 1991-1991.	1.4	11
304	Gene Mutations and Treatment Outcome in CLL Patients Treated with Chlorambucil (Chl) or Ofatumumab-Chl (O-Chl): Results from the Phase III Study COMPLEMENT1 (OMB110911). <i>Blood</i> , 2014, 124, 1992-1992.	1.4	4
305	Value of Minimal Residual Disease (MRD) Negative Status at Response Evaluation in Chronic Lymphocytic Leukemia (CLL): Combined Analysis of Two Phase III Studies of the German CLL Study Group (GCLLSG). <i>Blood</i> , 2014, 124, 23-23.	1.4	4
306	Clinical Activity of Abemaciclib (LY2835219), a Cell Cycle Inhibitor Selective for CDK4 and CDK6, in Patients with Relapsed or Refractory Mantle Cell Lymphoma. <i>Blood</i> , 2014, 124, 3067-3067.	1.4	15

#	ARTICLE	IF	CITATIONS
307	Efficacy and Safety of Ibrutinib in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Leukemia with 17p Deletion: Results from the Phase II RESONATE-1 Trial. <i>Blood</i> , 2014, 124, 327-327.	1.4	33
308	Second Interim Analysis of a Phase 3 Study of Idelalisib (ZYDELIGÂ®) Plus Rituximab (R) for Relapsed Chronic Lymphocytic Leukemia (CLL): Efficacy Analysis in Patient Subpopulations with Del(17p) and Other Adverse Prognostic Factors. <i>Blood</i> , 2014, 124, 330-330.	1.4	61
309	Salvage Therapy with Obinutuzumab (GA101) Plus Chlorambucil (Clb) after Treatment Failure of Clb Alone in Patients with Chronic Lymphocytic Leukemia (CLL) and Comorbidities: Results of the CLL11 Study. <i>Blood</i> , 2014, 124, 3327-3327.	1.4	7
310	Preliminary Results of a Phase 1b Study (GO28440) Combining GDC-0199 (ABT-199) with Bendamustine/Rituximab in Patients with Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia. <i>Blood</i> , 2014, 124, 3337-3337.	1.4	6
311	Preliminary Safety Results from the Phase IIIb GREEN Study of Obinutuzumab (GA101) Alone or in Combination with Chemotherapy for Previously Untreated or Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2014, 124, 3345-3345.	1.4	14
312	Single-Agent Ibrutinib Demonstrates Safety and Durability of Response at 2 Years Follow-up in Patients with Relapsed or Refractory Mantle Cell Lymphoma: Updated Results of an International, Multicenter, Open-Label Phase 2 Study. <i>Blood</i> , 2014, 124, 4453-4453.	1.4	13
313	Good Tolerance of Lenalidomide Maintenance Therapy in Patients with High Risk Profile Chronic Lymphocytic Leukemia (CLL) after Frontline Chemoimmunotherapy: Preliminary Safety Overview of the CLLM1 Trial of the German CLL Study Group (GCLLSG). <i>Blood</i> , 2014, 124, 4699-4699.	1.4	2
314	Advances in treating chronic lymphocytic leukemia. <i>F1000prime Reports</i> , 2014, 6, 65.	5.9	13
315	MicroRNAs in Hematologic Malignancies. , 2014, , 67-95.		0
316	Identification of the Antigenic Targets of the Major CLL-Derived Stereotyped BCRs and First Demonstration of Sub-Subsets. <i>Blood</i> , 2014, 124, 298-298.	1.4	0
317	Charting Unique Signatures of Somatic Hypermutation Amongst Chronic Lymphocytic Leukemia Patients Expressing IGHV4-34 Clonotypic B Cell Receptors. <i>Blood</i> , 2014, 124, 1969-1969.	1.4	0
318	Telomere Length and Outcome of Allogeneic Stem Cell Transplantation for Poor Risk Chronic Lymphocytic Leukemia: Results from the GCLLSG CLL3X Trial. <i>Blood</i> , 2014, 124, 1951-1951.	1.4	0
319	Chronic Lymphocytic Leukemia-Derived Extracellular Vesicles Contain a Distinctive Proteome, As Well As Specific Micro RNAs and Y RNAs. <i>Blood</i> , 2014, 124, 1968-1968.	1.4	28
320	NFATc1 Is Transcriptionally Activated in Chronic Lymphocytic Leukemia (CLL) By Promotor DNA-Hypomethylation Which Correlates with in-Vitro Vulnerability to Calcineurin Inhibitors. <i>Blood</i> , 2014, 124, 1941-1941.	1.4	6
321	High-Resolution Genomic Copy Number Analysis on Sequential Samples from the CLL8 Trial: Relation Between Clonal Evolution and Defects in DNA Damage Response?. <i>Blood</i> , 2014, 124, 1964-1964.	1.4	0
322	High Dose-Chemotherapy Followed By Autologous Peripheral Blood Stem Cell Transplantation for Patients with Refractory or Recurrent Primary Central Nervous System Lymphoma â€“Results of a Multicenter Study By the Germany Collaborative PCNSL Study Group. <i>Blood</i> , 2014, 124, 2527-2527.	1.4	0
323	Allogeneic HCT in Patients with 17p-CLL: Results of a Non-Interventional Study of the EBMT & Eric. <i>Blood</i> , 2014, 124, 1224-1224.	1.4	0
324	The Flavonoid Wogonin Reduces CLL Cell Survival in Vitro and Leukemia Development in Eµ-TCL1 Mice By Targeting Aberrant TNF Receptor Signaling. <i>Blood</i> , 2014, 124, 1966-1966.	1.4	0

#	ARTICLE	IF	CITATIONS
325	High Resolution Genomic Profiling of Primary "Ultra High Risk" and Refractory Chronic Lymphocytic Leukemia: Results from the CLL2O Trial. <i>Blood</i> , 2014, 124, 3288-3288.	1.4	0
326	Genomic Mechanisms of 17p / TP53 Loss in Primary "ultra High-risk" and Refractory Chronic Lymphocytic Leukemia: Results from the CLL2O Trial. <i>Blood</i> , 2014, 124, 2184-2184.	1.4	1
327	Induction Treatment with Alemtuzumab Combined with Polychemotherapy Containing Fludarabine, Cyclophosphamide and Mitoxantrone (FCM) Followed By Alemtuzumab Maintenance in Patients with T-Cell Prolymphocytic Leukaemia (T-PLL): First Analysis of a Prospective Multicenter Phase-II-Trial (T-PLL2) Conducted By the German CLL Study Group (GCLLSG). <i>Blood</i> , 2014, 124, 1999-1999.	1.4	0
328	17p Deletion in Chronic Lymphocytic Leukemia. <i>Hematology/Oncology Clinics of North America</i> , 2013, 27, 289-301.	2.2	13
329	Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma. <i>New England Journal of Medicine</i> , 2013, 369, 507-516.	27.0	1,449
330	NOTCH1, SF3B1, and TP53 mutations in fludarabine-refractory CLL patients treated with alemtuzumab: results from the CLL2H trial of the GCLLSG. <i>Blood</i> , 2013, 122, 1266-1270.	1.4	68
331	ESMO Guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL). <i>Annals of Oncology</i> , 2013, 24, 561-576.	1.2	193
332	Missing the notch in NOTCH1. <i>Leukemia and Lymphoma</i> , 2013, 54, 1579-1580.	1.3	0
333	Inhibitor kinazy Brutona u chorych z nawrotowym lub opornym na leczenie chłoniakiem z komórkami p <sub>17</sub> aszcza " wyniki międzynarodowego, wielośrodowego, badania II fazy z ibrutinibem (PCI-32765) " EHA.3 Encore. <i>Acta Haematologica Polonica</i> , 2013, 44, 314-318.		1
334	The gene expression signature associated with TP53 mutation/deletion in chronic lymphocytic leukaemia is dominated by the underexpression of TP53 and other genes on chromosome 17p. <i>British Journal of Haematology</i> , 2013, 160, 53-62.	2.5	8
335	Lenalidomide reduces survival of chronic lymphocytic leukemia cells in primary cocultures by altering the myeloid microenvironment. <i>Blood</i> , 2013, 121, 2503-2511.	1.4	41
336	The VEGF receptor, neuropilin-1, represents a promising novel target for chronic lymphocytic leukemia patients. <i>International Journal of Cancer</i> , 2013, 133, 1489-1496.	5.1	44
337	Epigenetic Upregulation of lncRNAs at 13q14.3 in Leukemia Is Linked to the In Cis Downregulation of a Gene Cluster That Targets NF-κB. <i>PLoS Genetics</i> , 2013, 9, e1003373.	3.5	134
338	Overview of available p53 function tests in relation to TP53 and ATM gene alterations and chemoresistance in chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2013, 54, 1849-1853.	1.3	15
339	Sequential chemoimmunotherapy of fludarabine, mitoxantrone, and cyclophosphamide induction followed by alemtuzumab consolidation is effective in T-cell prolymphocytic leukemia. <i>Cancer</i> , 2013, 119, 2258-2267.	4.1	56
340	Extracellular vesicles in chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2013, 54, 1826-1830.	1.3	15
341	Second-line therapies of patients initially treated with fludarabine and cyclophosphamide or fludarabine, cyclophosphamide and rituximab for chronic lymphocytic leukemia within the CLL8 protocol of the German CLL Study Group. <i>Leukemia and Lymphoma</i> , 2013, 54, 1821-1822.	1.3	26
342	TCL1A and ATM are co-expressed in chronic lymphocytic leukemia cells without deletion of 11q. <i>Haematologica</i> , 2013, 98, 269-273.	3.5	5

#	ARTICLE	IF	CITATIONS
343	<i>BRAF</i> mutations in chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2013, 54, 1177-1182.	1.3	45
344	Autoantigenic targets of B-cell receptors derived from chronic lymphocytic leukemias bind to and induce proliferation of leukemic cells. <i>Blood</i> , 2013, 121, 4708-4717.	1.4	36
345	Telomere length in mantle cell lymphoma. <i>Blood</i> , 2013, 121, 1184-1187.	1.4	19
346	TP53, SF3B1, and NOTCH1 mutations and outcome of allotransplantation for chronic lymphocytic leukemia: six-year follow-up of the GCLLSG CLL3X trial. <i>Blood</i> , 2013, 121, 3284-3288.	1.4	96
347	Germline Allele-Specific Expression of DAPK1 in Chronic Lymphocytic Leukemia. <i>PLoS ONE</i> , 2013, 8, e55261.	2.5	24
348	Progranulin Is a Novel Independent Predictor of Disease Progression and Overall Survival in Chronic Lymphocytic Leukemia. <i>PLoS ONE</i> , 2013, 8, e72107.	2.5	26
349	TP53 Mutation or Deletion and Efficacy with Single-Agent Lenalidomide in Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) (CC-5013-CLL-009 Study). <i>Blood</i> , 2013, 122, 1638-1638.	1.4	3
350	A Multicenter, Phase IV Observational Study Of Ofatumumab In Chronic Lymphocytic Leukemia (CLL): A European Research Initiative On CLL (ERIC) Study. <i>Blood</i> , 2013, 122, 1645-1645.	1.4	2
351	Role Of High-Dose Cytarabine and Total Body Irradiation Conditioning before Autologous Stem Cell Transplantation In Mantle Cell Lymphoma - A Comparison Of Nordic MCL2, HOVON 45, and European MCL Younger Trials. <i>Blood</i> , 2013, 122, 3367-3367.	1.4	6
352	Overall Survival In Early Stage Chronic Lymphocytic Leukemia Patients With Treatment Indication Due To Disease Progression: Follow-Up Data Of The CLL1 Trial Of The German CLL Study Group (GCLLSG). <i>Blood</i> , 2013, 122, 4127-4127.	1.4	5
353	Early Versus Deferred Treatment With Combined Fludarabine, Cyclophosphamide and Rituximab (FCR) Improves Event-Free Survival In Patients With High-Risk Binet Stage A Chronic Lymphocytic Leukemia â€œ First Results Of a Randomized German-French Cooperative Phase III Trial. <i>Blood</i> , 2013, 122, 524-524.	1.4	32
354	Chemoimmunotherapy With Fludarabine (F), Cyclophosphamide (C), and Rituximab (R) (FCR) Versus Bendamustine and Rituximab (BR) In Previously Untreated and Physically Fit Patients (pts) With Advanced Chronic Lymphocytic Leukemia (CLL): Results Of a Planned Interim Analysis Of The CLL10 Trial, An International, Randomized Study Of The German CLL Study Group (GCLLSG). <i>Blood</i> , 2013, 122, 526-526.	1.4	40
355	NOTCH1 Mutation and Treatment Outcome In CLL Patients Treated With Chlorambucil (Chl) Or Ofatumumab-Chl (O-Chl): Results From The Phase III Study Complement 1 (OMB110911). <i>Blood</i> , 2013, 122, 527-527.	1.4	9
356	Head-To-Head Comparison Of Obinutuzumab (GA101) Plus Chlorambucil (Clb) Versus Rituximab Plus Clb In Patients With Chronic Lymphocytic Leukemia (CLL) and Co-Existing Medical Conditions (Comorbidities): Final Stage 2 Results Of The CLL11 Trial. <i>Blood</i> , 2013, 122, 6-6.	1.4	21
357	Telomere Length and Treatment Outcome In Chronic Lymphocytic Leukemia: Results From The CLL8 Trial. <i>Blood</i> , 2013, 122, 671-671.	1.4	3
358	Obinutuzumab (GA101) plus chlorambucil (Clb) or rituximab (R) plus Clb versus Clb alone in patients with chronic lymphocytic leukemia (CLL) and preexisting medical conditions (comorbidities): Final stage 1 results of the CLL11 (BO21004) phase III trial.. <i>Journal of Clinical Oncology</i> , 2013, 31, 7004-7004.	1.6	20
359	Use of tumor genomic profiling to reveal mechanisms of resistance to the BTK inhibitor ibrutinib in chronic lymphocytic leukemia (CLL).. <i>Journal of Clinical Oncology</i> , 2013, 31, 7014-7014.	1.6	19
360	A comprehensive prognostic index for patients with CLL.. <i>Journal of Clinical Oncology</i> , 2013, 31, 7015-7015.	1.6	1

#	ARTICLE	IF	CITATIONS
361	Novel Gene Mutations In Chronic Lymphocytic Leukemia: Prevalence and Clinical Implications In A Series Of 3185 Cases - Initial Results From The European Research Initiative On CLL. <i>Blood</i> , 2013, 122, 1614-1614.	1.4	0
362	Microenvironmental Factors and The Role Of Tumor Necrosis Factor Receptor Type 1 (TNFR-1) In Chronic Lymphocytic Leukemia. <i>Blood</i> , 2013, 122, 4149-4149.	1.4	0
363	Heterogeneity and Evolution Of DNA Methylation In Chronic Lymphocytic Leukemia. <i>Blood</i> , 2013, 122, 1626-1626.	1.4	0
364	ADARB1 Is Involved In a Reduced Maturation Of The miR15a/Mir-16-1 Family In Chronic Lymphocytic Leukemia. <i>Blood</i> , 2013, 122, 1252-1252.	1.4	1
365	Prognostic Assessment In Patients With Chronic Lymphocytic Leukemia (CLL) In Clinical Practice: A European Research Initiative On CLL (ERIC) Survey. <i>Blood</i> , 2013, 122, 4156-4156.	1.4	1
366	Autologous and Allogeneic Stem-Cell Transplantation for Transformed Chronic Lymphocytic Leukemia (Richter's Syndrome): A Retrospective Analysis From the Chronic Lymphocytic Leukemia Subcommittee of the Chronic Leukemia Working Party and Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. <i>Journal of Clinical Oncology</i> , 2012, 30, 2211-2217.	1.6	110
367	Early autologous stem cell transplantation for chronic lymphocytic leukemia: long-term follow-up of the German CLL Study Group CLL3 trial. <i>Blood</i> , 2012, 119, 4851-4859.	1.4	27
368	CLL and deletion 13q14: merely the miRs?. <i>Blood</i> , 2012, 119, 2974-2975.	1.4	7
369	Risk categories and refractory CLL in the era of chemoimmunotherapy. <i>Blood</i> , 2012, 119, 4101-4107.	1.4	107
370	Synergy between PI3K Signaling and MYC in Burkitt Lymphomagenesis. <i>Cancer Cell</i> , 2012, 22, 167-179.	16.8	251
371	Final results of a multicenter phase 1 study of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2012, 53, 417-423.	1.3	56
372	Cellular origin and pathophysiology of chronic lymphocytic leukemia. <i>Journal of Experimental Medicine</i> , 2012, 209, 2183-2198.	8.5	227
373	High-resolution genomic profiling of chronic lymphocytic leukemia reveals new recurrent genomic alterations. <i>Blood</i> , 2012, 120, 4783-4794.	1.4	179
374	Minimal Residual Disease Quantification Is an Independent Predictor of Progression-Free and Overall Survival in Chronic Lymphocytic Leukemia: A Multivariate Analysis From the Randomized GCLLSG CLL8 Trial. <i>Journal of Clinical Oncology</i> , 2012, 30, 980-988.	1.6	397
375	miRNA-130a Targets <i>ATG2B</i> and <i>DICER1</i> to Inhibit Autophagy and Trigger Killing of Chronic Lymphocytic Leukemia Cells. <i>Cancer Research</i> , 2012, 72, 1763-1772.	0.9	185
376	Bendamustine in Combination With Rituximab for Previously Untreated Patients With Chronic Lymphocytic Leukemia: A Multicenter Phase II Trial of the German Chronic Lymphocytic Leukemia Study Group. <i>Journal of Clinical Oncology</i> , 2012, 30, 3209-3216.	1.6	388
377	Quantitative DNA Methylation Analysis Identifies a Single CpG Dinucleotide Important for ZAP-70 Expression and Predictive of Prognosis in Chronic Lymphocytic Leukemia. <i>Journal of Clinical Oncology</i> , 2012, 30, 2483-2491.	1.6	120
378	Assessment of p53 Functionality in Chronic Lymphocytic Leukemia by Different Assays; An Eric-Wide Approach.. <i>Blood</i> , 2012, 120, 2872-2872.	1.4	1

#	ARTICLE	IF	CITATIONS
379	Sequential High Dose Immuno-Chemotherapy Followed by Autologous Peripheral Blood Stem Cell Transplantation for Patients with Untreated Primary Central Nervous System Lymphoma - a Multicentre Study by the Collaborative PCNSL Study Group Freiburg. <i>Blood</i> , 2012, 120, 302-302.	1.4	17
380	Updated Interim Results of the Safety and Efficacy of Different Lenalidomide Starting Dose Regimens in Patients with Relapsed or Refractory (rel/ref) Chronic Lymphocytic Leukemia (CLL) (CC-5013-CLL-009) Tj ETQq0 0 Qr BT /Overdock 10 T	1.4	0
381	Gene Mutations and Treatment Outcome in Chronic Lymphocytic Leukemia: Results From the CLL8 Trial. <i>Blood</i> , 2012, 120, 433-433.	1.4	7
382	Extended Follow up of the CLL8 Protocol, a Randomized Phase-III Trial of the German CLL Study Group (GCLLSG) Comparing Fludarabine and Cyclophosphamide (FC) to FC Plus Rituximab (FCR) for Previously Untreated Patients with Chronic Lymphocytic Leukemia (CLL): Results On Survival, Progression-Free Survival, Delayed Neutropenias and Secondary Malignancies Confirm Superiority of the FCR Regimen. <i>Blood</i> , 2012, 120, 435-435.	1.4	20
383	Alemtuzumab Plus Oral Dexamethasone, Followed by Alemtuzumab Maintenance or Allogeneic Transplantation in Ultra High-Risk CLL: Updated Results From a Phase II Study of the Gclsg and fcgll/MW. <i>Blood</i> , 2012, 120, 716-716.	1.4	7
384	SF3B1, NOTCH1 and TP53 Mutations Do Not Affect the Outcome of Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for Chronic Lymphocytic Leukemia (CLL): 6-Year Follow-up of the Gclsg CLL3X Trial. <i>Blood</i> , 2012, 120, 966-966.	1.4	1
385	Lenalidomide Reduces Survival of Chronic Lymphocytic Leukemia Cells in Primary Co-Cultures by Altering the Myeloid Microenvironment. <i>Blood</i> , 2012, 120, 3894-3894.	1.4	0
386	Autoantigenic Targets of B-Cell Receptors (BCR) Derived From Chronic Lymphocytic Leukemias Bind to and Induce Proliferation of Leukemic Cells.. <i>Blood</i> , 2012, 120, 2884-2884.	1.4	0
387	TP53 Mutation Is an Independent Predictor of Poor Survival in Untreated Patients with CD20+ Aggressive B-Cell Lymphoma: Analysis within the Ricover-60 Trial. <i>Blood</i> , 2012, 120, 546-546.	1.4	0
388	Telomere Length in Mantle Cell Lymphoma.. <i>Blood</i> , 2012, 120, 2509-2509.	1.4	0
389	IL4 and CD40L Prevent Apoptosis of Chronic Lymphocytic Leukemia Cells Via Intracellular pSTAT6 and NFkB Signaling and Not Via Receptor Kinetics. <i>Blood</i> , 2012, 120, 3893-3893.	1.4	0
390	Microrna Expression in Fludarabine-Refractory CLL Implicates Independent Mechanisms of Resistance and Is Associated with Response and Progression Free Survival After Alemtuzumab Treatment: Results From the CLL2H Trial.. <i>Blood</i> , 2012, 120, 2874-2874.	1.4	0
391	The Use of Chemoimmunotherapy Improves the Outcome of Patients with Chronic Lymphocytic Leukaemia (CLL) â€“ a Metaanalysis of Five Trials of the German CLL Study Group (GCLLSG). <i>Blood</i> , 2012, 120, 3936-3936.	1.4	15
392	**102 Chemoimmunotherapy with Ofatumumab, Fludarabine and Cyclophosphamide (O-FC) in Previously Untreated Patients with Chronic Lymphocytic Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2011, 11, S119-S120.	0.4	2
393	4.13 Proposal of a New Prognostic Score for Previously Untreated Patients with Chronic Lymphocytic Leukemia Based on an Overall Survival Analysis of Three German CLL Study Group Phase III Trials. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2011, 11, S225-S227.	0.4	2
394	4.19 Prediction of Poor Outcome in Chronic Lymphocytic Leukemia Patients treated with FCR (Fludarabine, Cyclophosphamide, Rituximab) in the CLL8 Trial of the German CLL Study Group. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2011, 11, S230.	0.4	0
395	4.23 MDM2 Promotor Polymorphism and Disease Characteristics in CLL: Individual Patient Data Meta-Analysis of 2598 CLL Patients. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2011, 11, S233-S235.	0.4	0
396	DNA damageâ€“induced transcriptional program in CLL: biological and diagnostic implications for functional p53 testing. <i>Blood</i> , 2011, 117, 1622-1632.	1.4	35

#	ARTICLE	IF	CITATIONS
397	Immune modulatory agents in hematopoietic malignancies. <i>Cancer Treatment Reviews</i> , 2011, 37, S2-S7.	7.7	1
398	Bendamustine Combined With Rituximab in Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia: A Multicenter Phase II Trial of the German Chronic Lymphocytic Leukemia Study Group. <i>Journal of Clinical Oncology</i> , 2011, 29, 3559-3566.	1.6	342
399	Chemoimmunotherapy with O-FC in previously untreated patients with chronic lymphocytic leukemia. <i>Blood</i> , 2011, 117, 6450-6458.	1.4	121
400	Genetics of Chronic Lymphocytic Leukemia. <i>Clinics in Laboratory Medicine</i> , 2011, 31, 649-658.	1.4	7
401	Chronic lymphocytic leukemia - genomics lead the way. <i>Haematologica</i> , 2011, 96, 1402-1405.	3.5	6
402	P53 and microRNAs in chronic lymphocytic leukemia. <i>Journal of Nucleic Acids Investigation</i> , 2011, 2, 8.	0.8	1
403	Limited clinical relevance of imaging techniques in the follow-up of patients with advanced chronic lymphocytic leukemia: results of a meta-analysis. <i>Blood</i> , 2011, 117, 1817-1821.	1.4	37
404	Inflammatory cytokines and signaling pathways are associated with survival of primary chronic lymphocytic leukemia cells in vitro: a dominant role of CCL2. <i>Haematologica</i> , 2011, 96, 408-416.	3.5	80
405	Nurse-like cells show deregulated expression of genes involved in immunocompetence. <i>British Journal of Haematology</i> , 2011, 154, 349-356.	2.5	32
406	Clinical efficacy of immunochemotherapy with fludarabine, epirubicin and rituximab in the treatment for chronic lymphocytic leukaemia and prolymphocytic leukaemia. <i>European Journal of Haematology</i> , 2011, 87, 426-433.	2.2	24
407	A novel Fc-engineered monoclonal antibody to CD37 with enhanced ADCC and high proapoptotic activity for treatment of B-cell malignancies. <i>Blood</i> , 2011, 118, 4159-4168.	1.4	91
408	Mutation analysis of the <i>TNFAIP3</i> (A20) tumor suppressor gene in CLL. <i>International Journal of Cancer</i> , 2011, 128, 1747-1750.	5.1	16
409	Importance of genetics in chronic lymphocytic leukemia. <i>Blood Reviews</i> , 2011, 25, 131-137.	5.7	75
410	Novel targeted treatment strategies for refractory chronic lymphocytic leukaemia. <i>Therapeutic Advances in Hematology</i> , 2011, 2, 249-265.	2.5	3
411	Treating chronic lymphocytic leukemia with thalidomide and lenalidomide. <i>Expert Opinion on Pharmacotherapy</i> , 2011, 12, 2857-2864.	1.8	19
412	MicroRNA-130a Targets ATG2B, AGO4 and DICER1, Inhibits Autophagy and Induces Cell Death in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2011, 118, 1768-1768.	1.4	1
413	Minimal Residual Disease (MRD) Re-Growth Kinetics Are An Independent Predictor for Progression Free Survival (PFS) in Chronic Lymphocytic Leukemia (CLL) and Are Related to Biologically Defined CLL-Subgroups Results From the CLL8 Trial of the German CLL Study Group (GCLLSC). <i>Blood</i> , 2011, 118, 1777-1777.	1.4	6
414	Correlations Between Ofatumumab Exposure and Treatment Outcomes for Patients with Chronic Lymphocytic Leukemia (CLL) Treated with Frontline Ofatumumab, Fludarabine, and Cyclophosphamide Chemoimmunotherapy. <i>Blood</i> , 2011, 118, 1793-1793.	1.4	2



#	ARTICLE	IF	CITATIONS
415	Alemtuzumab Plus Oral Dexamethasone, Followed by Alemtuzumab Maintenance or Allogeneic Transplantation in Ultra High-Risk CLL: Interim Analysis of a Phase II Study of the GCLLSG and fcgcll/MW. Blood, 2011, 118, 2854-2854.	1.4	2
416	Interim Results for the Safety and Efficacy of Different Lenalidomide Starting Dose Regimens in Subjects with Relapsed or Refractory Chronic Lymphocytic Leukemia (CC-5013-CLL-009 Study). Blood, 2011, 118, 2859-2859.	1.4	2
417	Cyclophosphamide, Adriamycin, Vincristine and Prednisone Plus Rituximab (CHOP-R) in Fludarabine (F) Refractory Chronic Lymphocytic Leukemia (CLL) or CLL with Autoimmune Cytopenia (AIC) or Richter's Transformation (RT): Final Analysis of a Phase II Study of the German CLL Study Group. Blood, 2011, 118, 2860-2860.	1.4	2
418	Prediction of Poor Outcome in CLL Patients Treated with FCR (Fludarabine, Cyclophosphamide,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 62	1.4	2
419	Uncovering Thalidomide Mechanism of Action: Neuropilin 1 Represents the Target of Antiangiogenic and Immunomodulatory Effect in Chronic Lymphocytic Leukemia. Blood, 2011, 118, 4608-4608.	1.4	0
420	The Toll-Like Receptor-Like Molecule CD180 and Soluble CD14 Transmit Survival Signals in B-Cell Chronic Lymphocytic Leukemia Cells Presumably by Acting As Co-Receptors,. Blood, 2011, 118, 3883-3883.	1.4	0
421	Prognostic Impact of Biallelic Versus Monoallelic Deletion 13q and the Proportion of Cells with Deletion 13q within the CLL8 Trial of the German CLL Study Group (GCLLSG). Blood, 2011, 118, 2841-2841.	1.4	0
422	Reduced c-FOS Is Associated with Poor Prognosis and Clinical Course in Chronic Lymphocytic Leukemia. Blood, 2011, 118, 2433-2433.	1.4	0
423	Role of Microenvironment-Associated Chemokines and Cytokines for Binet Stage A CLL Patients Included in a Prospective Trial (CLL1 trial) of the German CLL Study Group (GCLLSG): sil2Ralpha Is An Independent Predictor of Progression-Free Survival (PFS),. Blood, 2011, 118, 3869-3869.	1.4	0
424	SNP-Arrays Provide New Insights Into the Pathogenesis of Richter Syndrome (RS). Blood, 2011, 118, 263-263.	1.4	1
425	Proposal of A Prognostic Score for Previously Untreated Patients with Chronic Lymphocytic Leukemia Based on An Overall Survival Analysis of Three German CLL Study Group Phase III Trials. Blood, 2011, 118, 2831-2831.	1.4	0
426	Protein expression analysis of chronic lymphocytic leukemia defines the effect of genetic aberrations and uncovers a correlation of CDK4, P27 and P53 with hierarchical risk. Haematologica, 2010, 95, 1880-1888.	3.5	5
427	Gene expression factors as predictors of genetic risk and survival in chronic lymphocytic leukemia. Haematologica, 2010, 95, 102-109.	3.5	31
428	Spleen tyrosine kinase inhibition prevents chemokine- and integrin-mediated stromal protective effects in chronic lymphocytic leukemia. Blood, 2010, 115, 4497-4506.	1.4	167
429	Soluble CD14 is a novel monocyte-derived survival factor for chronic lymphocytic leukemia cells, which is induced by CLL cells in vitro and present at abnormally high levels in vivo. Blood, 2010, 116, 4223-4230.	1.4	60
430	High-throughput detection of nuclear factor- $\kappa$ B activity using a sensitive oligo-based chemiluminescent enzyme-linked immunosorbent assay. International Journal of Cancer, 2010, 127, 404-411.	5.1	25
431	CD5 <sup>+</sup> B cells from individuals with systemic lupus erythematosus express granzyme B. European Journal of Immunology, 2010, 40, 2060-2069.	2.9	51
432	MDM2 promotor polymorphism and disease characteristics in CLL. Leukemia Research, 2010, 34, 578-579.	0.8	3

#	ARTICLE	IF	CITATIONS
433	Lenalidomide treatment of chronic lymphocytic leukaemia patients reduces regulatory T cells and induces Th17 T helper cells. <i>British Journal of Haematology</i> , 2010, 148, 948-950.	2.5	55
434	<i>SYK</i> carries no activating point mutations in patients with chronic lymphocytic leukaemia (CLL). <i>British Journal of Haematology</i> , 2010, 150, 633-636.	2.5	12
435	From pathogenesis to treatment of chronic lymphocytic leukaemia. <i>Nature Reviews Cancer</i> , 2010, 10, 37-50.	28.4	503
436	Ofatumumab As Single-Agent CD20 Immunotherapy in Fludarabine-Refractory Chronic Lymphocytic Leukemia. <i>Journal of Clinical Oncology</i> , 2010, 28, 1749-1755.	1.6	541
437	Immunoglobulin Heavy Chain Variable Gene Usage and (Super)-antigen Drive in Chronic Lymphocytic Leukemia. <i>Clinical Cancer Research</i> , 2010, 16, 373-375.	7.0	5
438	Understanding and Managing Ultra High-Risk Chronic Lymphocytic Leukemia. Hematology American Society of Hematology Education Program, 2010, 2010, 481-488.	2.5	112
439	More (on) prognostic factors in chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2010, 51, 5-6.	1.3	1
440	Biological diversity and risk-adapted treatment of chronic lymphocytic leukemia. <i>Haematologica</i> , 2010, 95, 1441-1443.	3.5	11
441	Ofatumumab Combined With Fludarabine and Cyclophosphamide (O-FC) Shows High Activity in Patients With Previously Untreated Chronic Lymphocytic Leukemia: Results From a Randomized, Multicenter, International, Two-Dose, Parallel-Group Phase II Trial. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2010, 10, E33-E34.	0.4	11
442	Chronic Lymphocytic Leukemia: New Concepts for Future Therapy. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2010, 10, 369-378.	0.4	10
443	Moving from prognostic to predictive factors in chronic lymphocytic leukaemia (CLL). <i>Best Practice and Research in Clinical Haematology</i> , 2010, 23, 71-84.	1.7	55
444	<i>TP53</i> Mutation and Survival in Chronic Lymphocytic Leukemia. <i>Journal of Clinical Oncology</i> , 2010, 28, 4473-4479.	1.6	523
445	Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the German CLL Study Group CLL3X trial. <i>Blood</i> , 2010, 116, 2438-2447.	1.4	273
446	Alternating Courses of 3x CHOP and 3x DHAP Plus Rituximab Followed by a High Dose ARA-C Containing Myeloablative Regimen and Autologous Stem Cell Transplantation (ASCT) Is Superior to 6 Courses CHOP Plus Rituximab Followed by Myeloablative Radiochemotherapy and ASCT In Mantle Cell Lymphoma: Results of the MCL Younger Trial of the European Mantle Cell Lymphoma Network (MCL) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	1.4	27
447	Final Results of the Phase I Study of Lenalidomide In Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL-001 Study). <i>Blood</i> , 2010, 116, 1376-1376.	1.4	1
448	Allogeneic Stem Cell Transplantation Can Overcome the Adverse Prognostic Impact of TP53 Mutation In Chronic Lymphocytic Leukemia (CLL): Results From the GCLLSG CLL3x Trial. <i>Blood</i> , 2010, 116, 2357-2357.	1.4	3
449	Genetics of Patients with F-Refractory CLL or Early Relapse After FC or FCR: Results From the CLL8 Trial of the GCLLSG. <i>Blood</i> , 2010, 116, 2427-2427.	1.4	11
450	High-Resolution SNP-Array Profiling of Chronic Lymphocytic Leukemia. <i>Blood</i> , 2010, 116, 50-50.	1.4	1

#	ARTICLE	IF	CITATIONS
451	Interim Analysis of EFC6663, a Multicenter Phase 2 Study of Alvocidib (flavopiridol), Demonstrates Clinical Responses Among Patients with Fludarabine Refractory CLL. <i>Blood</i> , 2010, 116, 58-58.	1.4	9
452	Serum Factors Predict Therapeutic Outcome In Patients with Chronic Lymphocytic Leukemia Treated In the CLL8 Trial of the German CLL Study Group (GCLLSG). <i>Blood</i> , 2010, 116, 918-918.	1.4	2
453	Subcutaneous Alemtuzumab Combined with Oral Dexamethasone, Followed by Alemtuzumab Maintenance or Allo-SCT In CLL with 17p- or Refractory to Fludarabine " Interim Analysis of the CLL20 Trial of the GCLLSG and FCGCLL/MW. <i>Blood</i> , 2010, 116, 920-920.	1.4	16
454	Final Analysis From the International Trial of Single-Agent Ofatumumab In Patients with Fludarabine-Refractory Chronic Lymphocytic Leukemia. <i>Blood</i> , 2010, 116, 921-921.	1.4	9
455	Refractory chronic lymphocytic leukemia - new therapeutic strategies. <i>Oncotarget</i> , 2010, 1, 472-482.	1.8	18
456	IGHV-Mutation Status, IGHV-Gene Usage and Chromosomal Aberrations In CLL: Pooled Analysis within First-Line Clinical Trials of the German CLL Study Group (GCLLSG). <i>Blood</i> , 2010, 116, 3609-3609.	1.4	0
457	Exceptional In Vitro Activity of CD37 Antibodies In CLL. <i>Blood</i> , 2010, 116, 2460-2460.	1.4	1
458	Induction Therapy with Idarubicin and Etoposide Combined with Sequential or Concurrent Azacitidine In Patients with High-Risk Acute Myeloid Leukemia: Pilot-Phase of the AMLSG 12-09 Study. <i>Blood</i> , 2010, 116, 2184-2184.	1.4	0
459	Maturation of the miR15a/miR16-1 Family Is Impaired In Chronic Lymphocytic Leukaemia. <i>Blood</i> , 2010, 116, 53-53.	1.4	0
460	Refractory chronic lymphocytic leukemia--new therapeutic strategies. <i>Oncotarget</i> , 2010, 1, 472-82.	1.8	12
461	Chemoimmunotherapy in chronic lymphocytic leukemia. <i>Clinical Advances in Hematology and Oncology</i> , 2010, 8, 867-8.	0.3	0
462	BCL2-938C>A polymorphism and disease progression in chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2009, 50, 1837-1842.	1.3	12
463	miR-34a as part of the resistance network in chronic lymphocytic leukemia. <i>Blood</i> , 2009, 113, 3801-3808.	1.4	258
464	Fatal <i>Ophiostoma piceae</i> infection in a patient with acute lymphoblastic leukaemia. <i>Journal of Medical Microbiology</i> , 2009, 58, 381-385.	1.8	14
465	A Novel Paradigm to Trigger Apoptosis in Chronic Lymphocytic Leukemia. <i>Cancer Research</i> , 2009, 69, 8977-8986.	0.9	55
466	Danish CLL2aCS Study revisited: FISH on a cohort with a 20aEyr followaEup confirms the validity of the hierarchical model of genomic aberrations in chronic lymphocytic leukaemia. <i>European Journal of Haematology</i> , 2009, 83, 156-158.	2.2	6
467	Chronic lymphocytic leukemia and 13q14: miRs and more. <i>Leukemia and Lymphoma</i> , 2009, 50, 502-505.	1.3	42
468	Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial. <i>Blood</i> , 2009, 114, 2589-2597.	1.4	253

#	ARTICLE	IF	CITATIONS
469	Treatment resistance in chronic lymphocytic leukemia—the role of the p53 pathway. <i>Leukemia and Lymphoma</i> , 2009, 50, 510-513.	1.3	35
470	Therapy with the FCR regimen does not overcome chronic lymphocytic leukemia biology: aberrant p53 expression predicts response and survival. <i>Leukemia and Lymphoma</i> , 2009, 50, 1559-1561.	1.3	3
471	Subcutaneous Alemtuzumab in Fludarabine-Refractory Chronic Lymphocytic Leukemia: Clinical Results and Prognostic Marker Analyses From the CLL2H Study of the German Chronic Lymphocytic Leukemia Study Group. <i>Journal of Clinical Oncology</i> , 2009, 27, 3994-4001.	1.6	257
472	TP53 Mutations and Outcome After Fludarabine and Cyclophosphamide (FC) or FC Plus Rituximab (FCR) in the CLL8 Trial of the GCLLSG.. <i>Blood</i> , 2009, 114, 1267-1267.	1.4	9
473	Bendamustine Combined with Rituximab (BR) in First-Line Therapy of Advanced CLL: A Multicenter Phase II Trial of the German CLL Study Group (GCLLSG).. <i>Blood</i> , 2009, 114, 205-205.	1.4	38
474	Ofatumumab Combined with Fludarabine and Cyclophosphamide (O-FC) Shows High Activity in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL): Results From a Randomized, Multicenter, International, Two-Dose, Parallel Group, Phase II Trial.. <i>Blood</i> , 2009, 114, 207-207.	1.4	19
475	Chemoimmuno-Therapy with Fludarabine, Cyclophosphamide and Alemtuzumab (FC-Cam) in Patients with Relapsed or Genetic High-Risk CLL: Final Analysis of the CLL2L Trial of the German CLL Study Group.. <i>Blood</i> , 2009, 114, 209-209.	1.4	7
476	Identification of RHAMM-Derived CD8+ Restricted, Heteroclitical, Cryptic Epitope R9Y as a Promising Target for Immunotherapy of Chronic Lymphocytic Leukemia.. <i>Blood</i> , 2009, 114, 3034-3034.	1.4	1
477	Correlation Between Serum Ofatumumab Concentrations, Baseline Patient Characteristics and Clinical Outcomes in Patients with Fludarabine-Refractory Chronic Lymphocytic Leukemia (CLL) Treated with Single-Agent Ofatumumab.. <i>Blood</i> , 2009, 114, 3433-3433.	1.4	7
478	First-Line Treatment with Fludarabine (F), Cyclophosphamide (C), and Rituximab (R) (FCR) Improves Overall Survival (OS) in Previously Untreated Patients (pts) with Advanced Chronic Lymphocytic Leukemia (CLL): Results of a Randomized Phase III Trial On Behalf of An International Group of Investigators and the German CLL Study Group.. <i>Blood</i> , 2009, 114, 535-535.	1.4	142
479	Early Autologous Stem Cell Transplantation (autoSCT) May Overcome the Adverse Impact of Del 11q- in Poor-Risk Chronic Lymphocytic Leukemia (CLL): Results From the GCLLSG CLL3 Trial.. <i>Blood</i> , 2009, 114, 879-879.	1.4	2
480	Comprehensive Protein Expression Analysis of Chronic Lymphocytic Leukemia Uncovers a Correlation of CDK4, P27 and P53 with Hierarchical Risk and Suggests a Dichotomy of Apoptosis and Proliferation.. <i>Blood</i> , 2009, 114, 1255-1255.	1.4	0
481	A Novel Paradigm to Trigger Apoptosis in Chronic Lymphocytic Leukemia.. <i>Blood</i> , 2009, 114, 731-731.	1.4	0
482	Identification and Characterization of Peptide Ligands for Stereotyped Subset and Non-Subset B-Cell Receptors of Patients with M- and U-CLL.. <i>Blood</i> , 2009, 114, 4369-4369.	1.4	2
483	In Vitro Activity of the Type II Anti-CD20 Antibody GA101 in Refractory, Genetic High-Risk CLL.. <i>Blood</i> , 2009, 114, 2379-2379.	1.4	4
484	Detection of NF $\kappa$ B Activity in Primary CLL Cells Using a Sensitive Oligo-Based Chemiluminescent ELISA.. <i>Blood</i> , 2009, 114, 4709-4709.	1.4	0
485	In-Vitro Effect of the Small Molecule Thrombopoietin (TPO) Receptor Agonist Eltrombopag in Chronic Lymphocytic Leukemia (CLL).. <i>Blood</i> , 2009, 114, 4408-4408.	1.4	0
486	Neuropilin-1 — Novel, Promising Target for Chronic Lymphocytic Leukemia patients.. <i>Blood</i> , 2009, 114, 4392-4392.	1.4	1

#	ARTICLE	IF	CITATIONS
487	Delineation of distinct tumour profiles in mantle cell lymphoma by detailed cytogenetic, interphase genetic and morphological analysis. <i>British Journal of Haematology</i> , 2008, 142, 538-550.	2.5	39
488	First Demonstration of Leukemia Imaging with the Proliferation Marker $^{18}\text{F}$ -Fluorodeoxythymidine. <i>Journal of Nuclear Medicine</i> , 2008, 49, 1756-1762.	5.0	68
489	Molecular diagnostics in chronic lymphocytic leukemia – Pathogenetic and clinical implications. <i>Leukemia and Lymphoma</i> , 2008, 49, 864-873.	1.3	37
490	Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with long-term follow-up. <i>Blood</i> , 2008, 112, 3322-3329.	1.4	348
491	Allogeneic Hematopoietic Stem-Cell Transplantation for Chronic Lymphocytic Leukemia With 17p Deletion: A Retrospective European Group for Blood and Marrow Transplantation Analysis. <i>Journal of Clinical Oncology</i> , 2008, 26, 5094-5100.	1.6	157
492	The MDM2 -309 T/G promoter single nucleotide polymorphism does not alter disease characteristics in chronic lymphocytic leukemia. <i>Haematologica</i> , 2008, 93, 1111-1113.	3.5	34
493	Chronic lymphocytic leukemia and treatment resistance in cancer: The role of the p53 pathway. <i>Cell Cycle</i> , 2008, 7, 3810-3814.	2.6	72
494	Short telomeres are associated with genetic complexity, high-risk genomic aberrations, and short survival in chronic lymphocytic leukemia. <i>Blood</i> , 2008, 111, 2246-2252.	1.4	122
495	Response: Or both?. <i>Blood</i> , 2008, 111, 5756-5757.	1.4	1
496	Genomic aberrations in mantle cell lymphoma detected by interphase fluorescence in situ hybridization. Incidence and clinicopathological correlations. <i>Haematologica</i> , 2008, 93, 680-687.	3.5	41
497	Autoimmune conditions and chronic infections in chronic lymphocytic leukemia patients at diagnosis are associated with unmutated IgVH genes. <i>Haematologica</i> , 2008, 93, 1912-1916.	3.5	25
498	Identification of Genes Associated with Resistance and Response in Vivo to Therapy with Rituximab, Fludarabine and Cyclophosphamide in Patients with Chronic Lymphocytic Leukemia.. <i>Blood</i> , 2008, 112, 1622-1622.	1.4	2
499	Biologic and Clinical Markers for Outcome after Fludarabine (F) or F Plus Cyclophosphamide (FC) - Comprehensive Analysis of the CLL4 Trial of the GCLLSG.. <i>Blood</i> , 2008, 112, 2089-2089.	1.4	18
500	Preliminary Results of a Phase 1/2, Multi-Center, Open-Label Study (CLL- 001) Investigating a Stepwise Dose-Escalation Schedule of Lenalidomide in Relapsed or Refractory Chronic Lymphocytic Leukemia.. <i>Blood</i> , 2008, 112, 2104-2104.	1.4	5
501	Standardized MRD Flow and ASO IGH RQ-PCR for MRD Quantification in CLL Patients after Rituximab-Containing Immunochemotherapy – a Comparative Analysis in 574 Samples from the Randomized GCLLSG CLL8 Trial. <i>Blood</i> , 2008, 112, 3139-3139.	1.4	1
502	Induction of Apoptosis in CLL by Peptides Binding the B-Cell Antigen Receptor in Vitro. <i>Blood</i> , 2008, 112, 3151-3151.	1.4	1
503	Peptide Vaccination Induces Dynamic Changes in CD4+ and CD8+ T Cell Subsets: Report on the First Peptide Vaccination Trial in Patients with Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2008, 112, 3159-3159.	1.4	2
504	Effective Targeting of the PI3-K Pathway in CLL with NVP-BEZ235, a Novel Orally Available Dual PI3K/mTOR Inhibitor. <i>Blood</i> , 2008, 112, 3166-3166.	1.4	1

#	ARTICLE	IF	CITATIONS
505	Chemoimmuno-Therapy with Fludarabine, Cyclophosphamide and Alemtuzumab in Patients with Relapsed/Refractory CLL: Interim Analysis of the CLL2L Trial of the German CLL Study Group. Blood, 2008, 112, 3170-3170.	1.4	3
506	Immunochemotherapy with Fludarabine (F), Cyclophosphamide (C), and Rituximab (R) (FCR) Versus Fludarabine and Cyclophosphamide (FC) Improves Response Rates and Progression-Free Survival (PFS) of Previously Untreated Patients (pts) with Advanced Chronic Lymphocytic Leukemia (CLL). Blood, 2008, 112, 325-325.	1.4	99
507	Quantitative MRD Assessments Predict Progression Free Survival in CLL Patients Treated with Fludarabine and Cyclophosphamide with or without Rituximab – a Prospective Analysis in 471 Patients from the Randomized GCLLSG CLL8 Trial. Blood, 2008, 112, 326-326.	1.4	13
508	Ofatumumab (HuMax-CD20), a Novel CD20 Monoclonal Antibody, Is An Active Treatment for Patients with CLL Refractory to Both Fludarabine and Alemtuzumab or Bulky Fludarabine-Refractory Disease: Results from the Planned Interim Analysis of An International Pivotal Trial. Blood, 2008, 112, 328-328.	1.4	31
509	Subcutaneous Alemtuzumab (Campath) in Fludarabine-Refractory CLL: Final Results of the CLL2H Trial of the GCLLSG and Comprehensive Analysis of Prognostic Markers. Blood, 2008, 112, 329-329.	1.4	4
510	Bendamustine in Combination with Rituximab (BR) for Patients with Relapsed Chronic Lymphocytic Leukemia (CLL): A Multicentre Phase II Trial of the German CLL Study Group (GCLLSG). Blood, 2008, 112, 330-330.	1.4	54
511	Prognostic Factors for Outcome of Nonmyeloablative Allogeneic Stem Cell Transplantation (NST) in Poor-Risk Chronic Lymphocytic Leukemia (CLL): Final Results from a Prospective Multicenter Trial (GCLLSG CLL3X study). Blood, 2008, 112, 565-565.	1.4	6
512	Genomic Aberrations, VH Mutation Status and Outcome after Fludarabine and Cyclophosphamide (FC) or FC Plus Rituximab (FCR) in the CLL8 Trial. Blood, 2008, 112, 781-781.	1.4	19
513	Differential Diagnosis, Staging and Prognostic Factors. , 2008, , 103-119.		2
514	Mir-34a as Part of the Chemotherapy Resistance Network in Chronic Lymphocytic Leukemia.. Blood, 2008, 112, 1209-1209.	1.4	1
515	The Response to DNA Damage in CLL Cells Is Partly Determined by the Type of TP53 Mutation and Genomic Aberrations. Blood, 2008, 112, 3119-3119.	1.4	0
516	Molecular and Immunological Effects of Thalidomide in Chronic Lymphocytic Leukemia.. Blood, 2008, 112, 2092-2092.	1.4	5
517	Epimutation of the Tumor Suppressor Mechanism in 13q14.3 Involves Monoallelic Expression, Non-Coding RNA Genes and Dereglulation of NFkB Signalling. Blood, 2008, 112, 783-783.	1.4	0
518	17p Deletion in CLL: Detailed Analysis of TP53 Mutations, Alternative Mechanisms of p53 Inactivation, Clone Size and Clonal Evolution. Blood, 2008, 112, 782-782.	1.4	7
519	In-Vitro Treatment with the AKT-Inhibitor GSK 690693 Induces Cell Death in Lymphoma Cell Lines and in Primary CLL Cells and Is Followed by Caspase-3 Activation and Cytochrome C Release.. Blood, 2008, 112, 1589-1589.	1.4	1
520	TP53 Abnormalities in Chronic Lymphocytic Leukemia Exhibit a Disease Specific Profile: Meta-Analysis of 270 Mutations.. Blood, 2008, 112, 2077-2077.	1.4	1
521	Quantitative Gene Expression Analysis of Surrogate Markers for Genetic Risk Groups and Survival in CLL. Blood, 2008, 112, 4170-4170.	1.4	2
522	Advances in the use of alemtuzumab in CLL. Clinical Advances in Hematology and Oncology, 2008, 6, 23-4.	0.3	1

#	ARTICLE	IF	CITATIONS
523	Quantitative Gene Expression Deregulation in Mantle-Cell Lymphoma: Correlation With Clinical and Biologic Factors. <i>Journal of Clinical Oncology</i> , 2007, 25, 2770-2777.	1.6	54
524	Clonal evolution in chronic lymphocytic leukemia: acquisition of high-risk genomic aberrations associated with unmutated VH, resistance to therapy, and short survival. <i>Haematologica</i> , 2007, 92, 1242-1245.	3.5	195
525	Update on Genomic Profiling in Chronic Lymphocytic Leukemia. <i>Clinical Leukemia</i> , 2007, 1, 217-222.	0.2	0
526	Genetics and risk-stratified approach to therapy in chronic lymphocytic leukemia. <i>Best Practice and Research in Clinical Haematology</i> , 2007, 20, 439-453.	1.7	61
527	High rate of centrosome aberrations and correlation with proliferative activity in patients with untreated B-cell chronic lymphocytic leukemia. <i>International Journal of Cancer</i> , 2007, 121, 978-983.	5.1	12
528	Overexpression of the paternally expressed gene <i>PEG10</i> from the imprinted locus on chromosome 7q21 in high-risk B-cell chronic lymphocytic leukemia. <i>International Journal of Cancer</i> , 2007, 121, 1984-1993.	5.1	67
529	Proposals for standardized protocols for cytogenetic analyses of acute leukemias, chronic lymphocytic leukemia, chronic myeloid leukemia, chronic myeloproliferative disorders, and myelodysplastic syndromes. <i>Genes Chromosomes and Cancer</i> , 2007, 46, 494-499.	2.8	81
530	Reduced-intensity conditioning followed by T-cell depleted allogeneic stem cell transplantation for patients with chronic myeloid leukaemia and minimal residual disease at the time of transplant: high risk of molecular relapse. <i>British Journal of Haematology</i> , 2007, 136, 127-130.	2.5	12
531	p53 Inactivation in CLL: Pattern of 110 TP53 Mutations.. <i>Blood</i> , 2007, 110, 2064-2064.	1.4	3
532	Bendamustine in Combination with Rituximab (BR) for Patients with Relapsed Chronic Lymphocytic Leukemia (CLL): A Multicentre Phase II Trial of the German CLL Study Group (GCLLSG).. <i>Blood</i> , 2007, 110, 3106-3106.	1.4	11
533	Subcutaneous Alemtuzumab (MabCampath) in Fludarabine-Refractory CLL (CLL2H Trial of the GCLLSG).. <i>Blood</i> , 2007, 110, 3120-3120.	1.4	11
534	Thalidomide Alone and in Combination with Fludarabine Exerts Distinct Molecular and Antileukemic Effects in B-Cell Chronic Lymphocytic Leukemia.. <i>Blood</i> , 2007, 110, 3124-3124.	1.4	2
535	Allogeneic Hematopoietic Cell Transplantation for Chronic Lymphocytic Leukemia (CLL) with 17p Deletion: A Retrospective EBMT Analysis.. <i>Blood</i> , 2007, 110, 47-47.	1.4	5
536	Prospective Evaluation of Prognostic Parameters in Early Stage Chronic Lymphocytic Leukemia (CLL): Results of the CLL1-Protocol of the German CLL Study Group (GCLLSG).. <i>Blood</i> , 2007, 110, 625-625.	1.4	13
537	Prognostic Assessment of Three Single Nucleotide Polymorphisms (BCL2 rs938&gt;A, MTHFR Tj ETQq1 1 0,784314 rgBT /Overl	1.4	14
538	Gene Expression Signature of B-Cell Chronic Lymphocytic Leukemia with Trisomy 12.. <i>Blood</i> , 2007, 110, 2079-2079.	1.4	0
539	In-Vitro Treatment of Lymphoma Cell Lines with BAY 43-9006 (Sorafenib) Is Followed by Typical Features of Apoptosis and Down-Regulation of MCL-1 Pointing to an Efficacy of Sorafenib in the Treatment of Lymphoma.. <i>Blood</i> , 2007, 110, 1392-1392.	1.4	0
540	The Receptor for Hyaluronic Acid Mediated Motility (RHAMM): Characterization as an Immunotherapeutical Target in Chronic Lymphocytic Leukemia (CLL) and First Results of RHAMM-Derived Peptide Vaccination Trial.. <i>Blood</i> , 2007, 110, 2051-2051.	1.4	0

#	ARTICLE	IF	CITATIONS
541	BCRs of Mutated and Unmutated CLL Bind Peptides with Distinct Sequence Features: Evidence from Phage Display Libraries.. Blood, 2007, 110, 1118-1118.	1.4	0
542	Uncovering the Epigenetic Pathomechanism in 13q14.. Blood, 2007, 110, 487-487.	1.4	0
543	Autoimmune or Chronic Infectious Disease in B-CLL at Diagnosis: Association with Unmutated VH Gene Status and Unfavorable Cytogenetics.. Blood, 2007, 110, 3092-3092.	1.4	0
544	Strikingly homologous immunoglobulin gene rearrangements and poor outcome in VH3-21-using chronic lymphocytic leukemia patients independent of geographic origin and mutational status. Blood, 2006, 107, 2889-2894.	1.4	167
545	Distinct gene expression patterns in chronic lymphocytic leukemia defined by usage of specific VH genes. Blood, 2006, 107, 2090-2093.	1.4	54
546	Genetics, Gene Expression, and Targeted Therapies in Chronic Lymphocytic Leukemia. Current Drug Targets, 2006, 7, 1313-1327.	2.1	7
547	Risk Stratification in Chronic Lymphocytic Leukemia. Seminars in Oncology, 2006, 33, 186-194.	2.2	67
548	Ala228 variant of trail receptor 1 affecting the ligand binding site is associated with chronic lymphocytic leukemia, mantle cell lymphoma, prostate cancer, head and neck squamous cell carcinoma and bladder cancer. International Journal of Cancer, 2006, 118, 1831-1835.	5.1	43
549	Allelic silencing at the tumor-suppressor locus 13q14.3 suggests an epigenetic tumor-suppressor mechanism. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 7741-7746.	7.1	54
550	Molecular Imaging of Proliferation in Malignant Lymphoma. Cancer Research, 2006, 66, 11055-11061.	0.9	173
551	Additional Genetic High-Risk Features Such As 11q Deletion, 17p Deletion, and <i>V3-21</i> Usage Characterize Discordance of ZAP-70 and <i>VH</i> Mutation Status in Chronic Lymphocytic Leukemia. Journal of Clinical Oncology, 2006, 24, 969-975.	1.6	177
552	Antagonizing inactivated tumor suppressor genes and activated oncogenes by a versatile transgenesis system: application in mantle cell lymphoma. FASEB Journal, 2006, 20, 1188-1190.	0.5	21
553	Clonal Evolution in Chronic Lymphocytic Leukemia: Acquisition of High-Risk Genomic Aberrations Associated with Unmutated VH, Resistance to Therapy, and Short Survival.. Blood, 2006, 108, 296-296.	1.4	1
554	Occurrence of Chromosomal Translocations as Independent Prognostic Factor in Chronic Lymphocytic Leukemia.. Blood, 2006, 108, 2084-2084.	1.4	0
555	RHAMM/CD168 Is a Novel Leukemia Associated Antigen with Prognostic Value for Patients with B-Cell Chronic Lymphocytic Leukemia.. Blood, 2006, 108, 2773-2773.	1.4	0
556	Influence of MDM2 Single Nucleotide Polymorphism SNP309 on Disease Onset and Course in CLL.. Blood, 2006, 108, 4938-4938.	1.4	0
557	Array-CGH Based Genomic Profiling in B-Cell Chronic Lymphocytic Leukemia Reveals Specific Correlations of Genomic Imbalances and Prognostic Subgroups and Underlines the Consistency of Chromosomal Aberration Patterns within This Disease.. Blood, 2006, 108, 2083-2083.	1.4	0
558	Bone marrow transplantation nephropathy after an intensified conditioning regimen with radioimmunotherapy and allogeneic stem cell transplantation. Journal of Nuclear Medicine, 2006, 47, 278-86.	5.0	16



#	ARTICLE	IF	CITATIONS
559	188Re or 90Y-labelled anti-CD66 antibody as part of a dose-reduced conditioning regimen for patients with acute leukaemia or myelodysplastic syndrome over the age of 55: results of a phase I-II study. <i>British Journal of Haematology</i> , 2005, 130, 604-613.	2.5	92
560	Duplication of chromosome arms 9q and 11q: Evidence for a novel, 14q32 translocation-independent pathogenetic pathway in multiple myeloma. <i>Genes Chromosomes and Cancer</i> , 2005, 42, 78-81.	2.8	5
561	Translocation t(X;11)(q13;q23) in B-cell chronic lymphocytic leukemia disrupts two novel genes. <i>Genes Chromosomes and Cancer</i> , 2005, 42, 128-143.	2.8	34
562	Evidence for Distinct Pathomechanisms in Genetic Subgroups of Chronic Lymphocytic Leukemia Revealed by Quantitative Expression Analysis of Cell Cycle, Activation, and Apoptosis-Associated Genes. <i>Journal of Clinical Oncology</i> , 2005, 23, 3780-3792.	1.6	66
563	Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia. <i>Blood</i> , 2005, 107, 885-891.	1.4	524
564	In-Vitro Treatment of Chronic Lymphocytic Leukemia (CLL) Cells with Fludarabine, Etoposide and Alemtuzumab (Campath-1H) Reveals Different Rates and Mechanisms of Cell Death.. <i>Blood</i> , 2005, 106, 2112-2112.	1.4	1
565	Fludarabine Versus Fludarabine Plus Epirubicin in the Treatment of Chronic Lymphocytic Leukemia - Final Results of a German Randomized Phase-III Study.. <i>Blood</i> , 2005, 106, 2123-2123.	1.4	4
566	Graft Versus Host Disease-Like Syndrome after Autologous Stem Cell Transplantation in CLL Patients Treated with a TBI/Cy/Alemtuzumab (CAMPATH-1H) High-Dose Regimen.. <i>Blood</i> , 2005, 106, 2928-2928.	1.4	1
567	17p Deletion Predicts for Inferior Overall Survival after Fludarabine - Based First Line Therapy in Chronic Lymphocytic Leukemia: First Analysis of Genetics in the CLL4 Trial of the GCLLSC.. <i>Blood</i> , 2005, 106, 715-715.	1.4	41
568	The Paternally Expressed Gene 10 (PEG10) on Chromosome 7q21 Is Overexpressed and Imprinted in High-Risk B-CLL.. <i>Blood</i> , 2005, 106, 1221-1221.	1.4	0
569	Short Telomeres Are Associated with Genetic Instability and the Occurrence of High Risk Genomic Aberrations in Chronic Lymphocytic Leukemia.. <i>Blood</i> , 2005, 106, 1178-1178.	1.4	0
570	Strikingly Homologous Immunoglobulin Gene Rearrangements and Poor Outcome in VH3-21-Utilizing Chronic Lymphocytic Leukemia Independent of Geographical Origin and Mutational Status.. <i>Blood</i> , 2005, 106, 175-175.	1.4	6
571	MRD Kinetics Can Predict the Time to Relapse after Autologous Stem Cell Transplantation (SCT) in Chronic Lymphocytic Leukemia (CLL).. <i>Blood</i> , 2005, 106, 714-714.	1.4	1
572	ZAP-70 methylation and expression status in chronic lymphocytic leukemia. <i>Haematologica</i> , 2005, 90, 1012.	3.5	0
573	Microarray Gene Expression Profiling of B-Cell Chronic Lymphocytic Leukemia Subgroups Defined by Genomic Aberrations and <i>VH</i> Mutation Status. <i>Journal of Clinical Oncology</i> , 2004, 22, 3937-3949.	1.6	200
574	Automated array-based genomic profiling in chronic lymphocytic leukemia: Development of a clinical tool and discovery of recurrent genomic alterations. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004, 101, 1039-1044.	7.1	221
575	Molecular genetics and its clinical relevance. <i>Hematology/Oncology Clinics of North America</i> , 2004, 18, 827-848.	2.2	18
576	The prognostic impact of autologous stem cell transplantation in patients with chronic lymphocytic leukemia: a risk-matched analysis based on the VH gene mutational status. <i>Blood</i> , 2004, 103, 2850-2858.	1.4	101

#	ARTICLE	IF	CITATIONS
577	Graft-versus-leukemia activity may overcome therapeutic resistance of chronic lymphocytic leukemia with unmutated immunoglobulin variable heavy-chain gene status: implications of minimal residual disease measurement with quantitative PCR. <i>Blood</i> , 2004, 104, 2600-2602.	1.4	157
578	Early Autologous Stem Cell Transplantation (SCT) in Genetically Poor-Risk Chronic Lymphocytic Leukemia Is Feasible and Effective: Results from a Prospective Multicenter Study (GCLLSG CLL3) Tj ETQq0 0 0 rgBTjQverlock&10 Tf 50 69	1.4	0
579	Minimal Residual Disease (MRD) Kinetics after Autologous Stem Cell Transplantation for Chronic Lymphocytic Leukemia (CLL) Correlate to IgH VH Mutational Status and Predict Post Transplant Outcome: Real Time ASO-IgH PCR Results of the GCLLSG CLL3 Protocol.. <i>Blood</i> , 2004, 104, 147-147.	1.4	5
580	ZAP-70 Expression, VH-Mutation Status, Genomic Aberrations and Prognosis in Chronic Lymphocytic Leukemia.. <i>Blood</i> , 2004, 104, 1920-1920.	1.4	2
581	Consolidation with Alemtuzumab in First Remission Induces Pronounced MRD Reduction and Clinical Remissions - Update on a Randomized Phase III Trial of the German CLL Study Group (GCLLSG).. <i>Blood</i> , 2004, 104, 2506-2506.	1.4	4
582	Subcutaneous Campath-1H (Alemtuzumab) in Fludarabine-Refractory CLL: Interim Analysis of the CLL2h Study of the German CLL Study Group (GCLLSG).. <i>Blood</i> , 2004, 104, 478-478.	1.4	30
583	Protein Expression Patterns of Candidate Genes Involved in Apoptosis and Cell Cycle Control in Genetic Subgroups of Chronic Lymphocytic Leukemia.. <i>Blood</i> , 2004, 104, 2796-2796.	1.4	0
584	Prognostic Relevance of Lipoprotein Lipase (LPL) Expression in B-CLL.. <i>Blood</i> , 2004, 104, 177-177.	1.4	0
585	Differential Expression Patterns of Apoptosis and Cell Cycle Proteins after Staurosporine Treatment in EHEB (B-CLL) and JURKAT (T-ALL) Cell Lines.. <i>Blood</i> , 2004, 104, 4304-4304.	1.4	0
586	Correlation of Quantitative Gene Expression by RQ-PCR with Clinical and Biologic Factors in Mantle Cell Lymphoma.. <i>Blood</i> , 2004, 104, 696-696.	1.4	4
587	High ZAP-70 and Differential Expression of B-Cell Receptor Related Genes in Chronic Lymphocytic Leukemia with V3-21 Gene Usage.. <i>Blood</i> , 2004, 104, 773-773.	1.4	0
588	Protein Expression Analysis of Chromosome 12 Candidate Genes in Chronic Lymphocytic Leukemia (B-CLL).. <i>Blood</i> , 2004, 104, 4797-4797.	1.4	0
589	Value of comparative genomic hybridization and fluorescence in situ hybridization for molecular diagnostics in multiple myeloma. <i>British Journal of Haematology</i> , 2003, 122, 193-201.	2.5	38
590	Genetic analysis of de novo CD5+ diffuse large B-cell lymphomas suggests an origin from a somatically mutated CD5+ progenitor B cell. <i>Blood</i> , 2003, 101, 699-702.	1.4	41
591	Unmutated immunoglobulin variable heavy-chain gene status remains an adverse prognostic factor after autologous stem cell transplantation for chronic lymphocytic leukemia. <i>Blood</i> , 2003, 101, 2049-2053.	1.4	116
592	VH mutation status and VDJ rearrangement structure in mantle cell lymphoma: correlation with genomic aberrations, clinical characteristics, and outcome. <i>Blood</i> , 2003, 102, 3003-3009.	1.4	136
593	Campath-1Hâ€“Induced Complete Remission of Chronic Lymphocytic Leukemia despitep53Gene Mutation and Resistance to Chemotherapy. <i>New England Journal of Medicine</i> , 2002, 347, 452-453.	27.0	195
594	Down-regulation of candidate tumor suppressor genes within chromosome band 13q14.3 is independent of the DNA methylation pattern in B-cell chronic lymphocytic leukemia. <i>Blood</i> , 2002, 99, 4116-4121.	1.4	91

#	ARTICLE	IF	CITATIONS
595	Pathogenic complexity of gastric B-cell lymphoma. <i>Blood</i> , 2002, 100, 1095-1097.	1.4	8
596	Genetic Imbalances in Progressed B-Cell Chronic Lymphocytic Leukemia and Transformed Large-Cell Lymphoma (Richter's Syndrome). <i>American Journal of Pathology</i> , 2002, 161, 957-968.	3.8	86
597	Evidence for distinct pathomechanisms in B-cell chronic lymphocytic leukemia and mantle cell lymphoma by quantitative expression analysis of cell cycle and apoptosis-associated genes. <i>Blood</i> , 2002, 99, 4554-4561.	1.4	125
598	VH mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia. <i>Blood</i> , 2002, 100, 1410-1416.	1.4	690
599	V(H) mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia. <i>Blood</i> , 2002, 100, 1410-6.	1.4	206
600	CDNA microarray gene expression analysis of B-cell chronic lymphocytic leukemia proposes potential new prognostic markers involved in lymphocyte trafficking. <i>International Journal of Cancer</i> , 2001, 91, 474-480.	5.1	106
601	Molecular-cytogenetic comparison of mucosa-associated marginal zone B-cell lymphoma and large B-cell lymphoma arising in the gastro-intestinal tract. <i>Genes Chromosomes and Cancer</i> , 2001, 31, 316-325.	2.8	75
602	B-cell neoplasia associated gene with multiple splicing (BCMS): the candidate B-CLL gene on 13q14 comprises more than 560 kb covering all critical regions. <i>Human Molecular Genetics</i> , 2001, 10, 1275-1285.	2.9	81
603	t(11;14)-positive mantle cell lymphomas exhibit complex karyotypes and share similarities with B-cell chronic lymphocytic leukemia. , 2000, 27, 285-294.		137
604	BCMSUN, a candidate gene for B-cell chronic lymphocytic leukemia and mantle-cell lymphoma, has an independently expressed homolog on 1p22-p31,BCMSUN-like. <i>International Journal of Cancer</i> , 2000, 88, 692-697.	5.1	15
605	Genomic Aberrations and Survival in Chronic Lymphocytic Leukemia. <i>New England Journal of Medicine</i> , 2000, 343, 1910-1916.	27.0	2,967
606	Molecular Characterization of 11q Deletions Points to a Pathogenic Role of the ATM Gene in Mantle Cell Lymphoma. <i>Blood</i> , 1999, 94, 3262-3264.	1.4	114
607	Somatic ATM Mutations Indicate a Pathogenic Role of ATM in B-Cell Chronic Lymphocytic Leukemia. <i>Blood</i> , 1999, 94, 748-753.	1.4	233
608	Chromosome aberrations in B-cell chronic lymphocytic leukemia: reassessment based on molecular cytogenetic analysis. <i>Journal of Molecular Medicine</i> , 1999, 77, 266-281.	3.9	215
609	Exclusive Detection of the t(11;18)(q21;q21) in Extranodal Marginal Zone B Cell Lymphomas (MZBL) of MALT Type in Contrast to other MZBL and Extranodal Large B Cell Lymphomas. <i>American Journal of Pathology</i> , 1999, 155, 1817-1821.	3.8	124
610	Expression of Costimulatory Molecules in Low-Grade Mucosa-Associated Lymphoid Tissue-Type Lymphomas in Vivo. <i>American Journal of Pathology</i> , 1999, 155, 2019-2027.	3.8	44
611	Expressed sequences as candidates for a novel tumor suppressor gene at band 13q14 in B-cell chronic lymphocytic leukemia and mantle cell lymphoma. <i>Oncogene</i> , 1998, 16, 1891-1897.	5.9	139
612	11q Deletions Identify a New Subset of B-Cell Chronic Lymphocytic Leukemia Characterized by Extensive Nodal Involvement and Inferior Prognosis. <i>Blood</i> , 1997, 89, 2516-2522.	1.4	363

#	ARTICLE	IF	CITATIONS
613	Biallelic mutations in the ATM gene in T-prolymphocytic leukemia. <i>Nature Medicine</i> , 1997, 3, 1155-1159.	30.7	243
614	CDKN2 gene deletion is not found in chronic lymphoid leukaemias of B- and T-cell origin but is frequent in acute lymphoblastic leukaemia. <i>British Journal of Haematology</i> , 1995, 91, 865-870.	2.5	20
615	Molecular Cytogenetic Analysis of RB-1 Deletions in Chronic B-Cell Leukemias. <i>Leukemia and Lymphoma</i> , 1994, 16, 97-103.	1.3	24
616	Reciprocal translocation t(12;13)(p13;q14) in acute nonlymphoblastic leukemia: Report and cytogenetic analysis of two cases. <i>Cancer Genetics and Cytogenetics</i> , 1994, 77, 106-110.	1.0	13